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Abstract 
 
Systemic lupus erythematosus (SLE) affects a significant portion of young women of 
childbearing age worldwide, in particular those of non-white descent.  In the United States, the 
incidence ranges 8.1-11.4 per 100,000 among African-American, and 2.5-3.9 per 100,000 among 
Caucasian women. The prevalence is estimated 56-283 per 100,000 among African-American, 
and 17-71 per 100,000 among Caucasian women. Understanding the natural history of systemic 
lupus, its major complications such as cardiovascular disease and associated risk factors, 
identifying major biomarkers for timely and accurate diagnosis of the disease itself and its 
manifestations is of great public health importance, since this will help to reduce morbidity and 
mortality among lupus patients. 
The dissertation consists of three relevant chapters. The first chapter is an overview of 
candidate biomarkers for diagnosis of SLE. It includes a brief review of the role of complement 
molecules in SLE pathogenesis, evaluation of the past and current uses of complement in 
monitoring SLE disease activity, and summary of recent findings that propose a novel method of 
measuring complement activation to specifically and sensitively diagnose SLE.  The chapter 
concludes by discussing how this method may also support the resurgence of complement as a 
valuable biomarker of SLE disease activity. 
The second chapter is the cost effectiveness analysis of the novel diagnostic biomarker 
discussed in chapter one. The analysis shows that using the novel diagnostic biomarker along with 
the traditional tests can be cost effective for the population of patients contemplating SLE.  
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Chapter three is devoted to atherosclerosis as a major complication of SLE and to 
coronary calcification measured by electron beam tomography (EBT) as a major biomarker of 
subclinical atherosclerosis. The risk factors associated with subclinical vascular disease in 
women with SLE are also reported. It is concluded that atherosclerosis of the coronary arteries 
detected by EBT is highly prevalent in patients with SLE and is related to many potentially 
modifiable traditional, SLE-specific and inflammatory risk factors for vascular disease.  
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1 Complement Proteins as Biomarkers of SLE Disease Activity: State 
of Art 
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1.1 INTRODUCTION 
Systemic lupus erythematosus (SLE) is the most clinically and serologically diverse autoimmune 
disease and can affect virtually all organs in the body. The clinical manifestations in SLE are thought to 
arise from tissue inflammation characterized by immune complex deposition, complement activation, 
and blood vessel abnormalities. Clinically, SLE is difficult to diagnose and manage because of its 
heterogeneous presentation and unpredictable course that consists of periods of remission and 
exacerbation (flares). Although most flares are caused by reversible inflammatory processes, over time, 
they can lead to irreversible organ damage that greatly affects the morbidity and mortality of patients 
with SLE. Earlier and more accurate detection of disease flares would not only expedite appropriate 
treatment, but also reduce the frequency of unnecessary interventions that are often associated with 
significant adverse effects.   
A major barrier to the assessment of disease activity, the identification of patients at risk for 
flares and organ damage, and the evaluation of responses to treatment for SLE is the lack of reliable 
and specific biomarkers for diagnosis and monitoring of disease activity. Standard tests currently 
used to monitor SLE disease activity, including measurements of complement, anti-nuclear antibody 
(ANA), and anti-double stranded DNA (dsDNA) antibodies, are often inadequate in detecting active 
disease. However, recent discoveries in our laboratory of a novel method for measuring complement 
activation indicate that complement may yet be a promising indictor of SLE disease activity.  In this 
article, we briefly review the role of complement in SLE pathogenesis, evaluate the past and current 
uses of complement in monitoring SLE disease activity, and summarize our recent findings that 
propose a novel method of measuring complement activation to specifically and sensitively diagnose 
SLE.  We conclude by discussing how this method may also support the resurgence of complement 
as a valuable biomarker of SLE disease activity.    
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1.2 THE COMPLEMENT SYSTEM   
The complement system, an important component of the immune system, comprises a group of more than 20 plasma and membrane-
bound proteins that form three distinct pathways designed to protect against invasion of foreign pathogens (Figure 1-1). 
 
 
Figure 1-1. Pathways of the complement system.
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Many of the complement proteins exist as functionally inactive pro-proteins until 
appropriate events trigger their activation. Once activated, the proteins within each pathway 
undergo a cascade of sequential cleavage and release of biologically active fragments and self-
assembly into multimolecular complexes. In humans and other mammals, the complement system 
is controlled by many regulatory proteins to prevent over activation and unwanted inflammation.  
Traditionally, the complement system is traditionally thought to have four biological 
functions: activation of inflammation, opsonization, clearance of immune complexes, and osmotic 
lysis of invading microorganisms [1]. These functions are mediated by the soluble or surface-bound 
fragments of activated complement proteins, which in turn interact with specific membrane 
receptors expressed on various cell types. The soluble proteolytic fragments, C3a, C4a, and C5a, 
usually diffuse away from the activation site to stimulate inflammation via chemoattraction and 
activation of leukocytes. The larger fragments, C3b, C4b, and their derivatives (iC3b, C3d, iC4b, 
C4d), can opsonize microbial pathogens by remaining bound to their surface. The complement-
derived ligands on the pathogen surface facilitate phagocytosis by neutrophils and macrophages by 
binding to complement receptor (CR) 1 (for C3b and C4b), CR3 (for iC3b and iC4b), and perhaps 
CR4 (for iC3b and iC4b) expressed on phagocytes. C4b and C3b can also bind to immune 
complexes, preventing them from aggregating into insoluble complexes and enhancing their 
clearance. The clearance of C3b/C4b-opsonized immune complexes is believed to be mediated by 
erythrocytes that express CR1 and are capable of transporting immune complexes to macrophages 
[2]. Our recent studies [3] and those of other investigators [4] have demonstrated that complement 
proteins, particularly C1, C3, and C4, can bind to apoptotic cells and blebs, and thus may play an 
important role in maintaining immune tolerance by facilitating the clearance of autoantigen-
containing apopotic bodies [5,6]. C3d, the end cleavage product of C3, interacts with CR2 
expressed on B cells and may be involved in B cell activation and enhancement of humoral 
immune responses [7]. Finally, the C5b-9 membrane attack complexes (MACs) may perturb the 
integrity of the surface membrane of target cells, thereby stimulating various cellular functions (at 
sublytic doses) or causing cell lysis (at lytic doses). 
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1.3 COMPLEMENT ACTIVATION AND SLE   
The role of complement in SLE is both complex and paradoxical. Activation of the complement 
system is thought to contribute to tissue inflammation and damage in SLE as a consequence of 
autoimmune complex deposition [8,9]. However, a hereditary deficiency of one of several  
components of the classical pathway (C1, C2, or C4) has been associated with the development of 
SLE [5,6,10]. These apparently conflicting roles can be reconciled by studies performed during the 
past several years demonstrating that, although the complement system plays a role in maintaining 
immune tolerance to prevent the development of SLE [5,6,11,12], it also participates in the 
inflammatory processes once SLE is established [8,9,13]. 
 
1.3.1 COMPLEMENT AND THE ASSESSMENT OF SLE DISEASE ACTIVITY 
The classical complement pathway is thought to be activated during active states of SLE.  As a 
result, one might expect the extent of parent complement proteins converted to activation products 
to be related to the level of disease activity. Thus, measuring serum complement levels has been 
considered the "gold standard" for monitoring disease activity in SLE patients. Conventionally, 
complement activation is assessed by functional assays quantifying hemolytic activity (CH100 or 
CH50; measuring total complement activity) or by static measures of serum complement 
components such as C1q, C2, and C4 (classical pathway activation), factor B (alternative pathway 
activation), or C3 (representing the common terminal pathway). Since Vaughan et al. first reported 
an association between decreased complement and active SLE five decades ago [14], numerous 
studies have been conducted to evaluate the potential usefulness of these assays in monitoring SLE 
disease activity.  
Some investigators have found CH50 as well as serum C4 and C3 levels valuable as 
markers of SLE activity, while others have found them minimally useful (Table 1-1). Several 
lines of evidence support their utility. Decreased levels of CH50 and serum C3 and C4 have been 
associated with more severe lupus nephritis or extra-renal involvement.  Moreover, increased 
serum C3 levels have coincided significantly with remission of nephritis and decreased levels 
with its relapse.  In addition, decreases in serum C4 levels have preceded clinical exacerbation, 
and in some patients, serum C3 and C4 levels have normalized when disease flares resolved. In 
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contrast, serum C4 levels have remained normal in some SLE patients during disease flares, and 
decreased C4 levels have been documented in SLE patients with apparently inactive disease, 
arguing against a role for complement as indicators of SLE disease activity. Regarding the latter 
situation, it should be noted that the so-called “serologically active clinically quiescent (SACQ)” 
periods have been seen in many SLE patients [15,16]. During SACQ periods, the clinical disease 
is absent, but serological activity is evident.  Although complement levels do not generally 
correlate with long-term outcome, some patients with low levels of multiple complement 
components appear to be at higher risk for developing renal insufficiency [17].  
Collectively, these conflicting data have failed to provide convincing support for the role of 
low C3 and C4 or other complement abnormalities as reliable indicators or predictors of SLE 
disease activity. 
 
1.3.2 COMPLEMENT ACTIVATION PRODUCTS  
In view of the apparent shortcoming of measuring serum C3 and to assess SLE disease activity, 
many investigators have sought alternative approaches. Because measurement of C3 and C4 is 
primarily a static appraisal of an extremely dynamic process of activation, consumption, 
catabolism, and synthesis of these components, direct determination of complement activation 
products is thought to more precisely reflect complement activation in vivo. A number of 
complement activation products of the classical pathway (C1rs-C1 inhibitor complex, C2a, C4d), 
alternative pathway (Ba, Bb, C3b(Bb)p), and the common terminal pathway (C3a, iC3b, C3d, 
C5a, C5b-9 complex), have been investigated for their potential as disease markers or predictors 
in SLE (Table 1-2).  
Several investigators have reported that plasma concentrations of complement activation 
products, including C1-C1 inh complex, C3a, C4a, C5a, C3d, C4d, C5b-9 complex, Ba, and Bb, 
increase prior to or during clinical exacerbation.  However, increased C3d levels have been 
detected in a significant number of patients without clinical disease.  A number of studies have 
reported little or no correlation between plasma levels of complement activation products and SLE 
disease activity. As was the case in the numerous studies evaluating complement component 
measurements, the studies of complement activation products as markers of SLE disease activity 
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have been inconclusive. The search for the ideal marker of disease activity in SLE warrants more 
intensive, coordinated efforts from both clinicians and basic science researchers.  
 
Potential reasons why complement measures do not correlate with SLE disease activity 
The discrepant reports regarding the value of measuring serum C4, C3, and various 
complement activation products to monitor SLE disease activity may originate from several 
biochemical or genetic factors. First, the range of serum C3 and C4 levels among healthy 
individuals varies widely and overlaps with that observed in SLE patients. Second, standard 
laboratory tests measure the concentration of C3 and C4 molecules in circulation irrespective of 
their functional status. Third, the acute phase response during inflammation may lead to an 
increase in C4 and C3 synthesis [18], thereby counterbalancing and masking their consumption 
during activation. Fourth, increased catabolism independent of inflammation [19-21] as well as 
reduced synthesis of C4 and C3 [22,23] have been reported to occur in patients with SLE, a 
situation that likely interferes with static measures of C4 and C3 levels. Fifth, genetic variations 
such as a partial deficiency of C4, commonly present in the general population as well as among 
SLE patients [24-26], may lead to lower than normal serum C4 levels in some patients because 
of decreased synthesis rather than increased complement consumption during disease flares. 
Sixth, when immune complexes deposit in tissues, complement activation may be localized and 
not reflected by the levels of complement products in the systemic circulation. Similarly, there 
are factors that could influence the measurements of complement activation products. Many of 
the activation products have an undefined, most likely short, half-life both in vivo and in vitro. 
Moreover, complement activation may occur in vitro after blood sampling. As a result, current 
measures of complement activation products may not accurately reflect complement activation in 
the patient.  
Variability in clinical factors and study design may also contribute to inconclusiveness of 
the study results. SLE patient populations are inherently heterogeneous with respect to disease 
activity and organ involvement. Such heterogeneity within a given population of patients may 
obscure subtle yet clinically significant results in a cross-sectional study. Furthermore, it has been 
difficult to standardize the accurate diagnosis of SLE and definition of a disease flare.  Before the 
recent development of several activity assessment instruments (e.g., SLE Disease Activity Index, 
Systemic Lupus Activity Measure, British Isles Lupus Assessment Group), widely different criteria 
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were used in defining SLE disease activity and flares. In many of the early studies, investigators 
used qualitative definitions, such as the occurrence of exacerbating manifestations and the 
physician’s assessment and decision to change medications. Such discrepancies in study design 
undoubtedly further contribute to the difficulties in interpreting and comparing results obtained 
from different studies.  
Considering the numerous confounding factors outlined above, it is not surprising that the 
role of complement as a biomarker of SLE disease activity remains inconclusive. However, it is 
important to point out that serum complement measures can be informative when performed over 
time in the same patient and when the results are interpreted based on the specific genetic and 
clinical status of the patient.  As discussed below, they may also be of value in assessing disease 
activity or predicting outcome in particular circumstances, such as with certain organ involvement 
and during pregnancy.  
 
1.3.3 COMPLEMENT AND ORGAN-SPECIFIC INVOLVEMENT IN SLE 
One of the most serious clinical manifestations of SLE is nephritis. Nephritic flare has been 
shown to be a predictor of poor long-term outcome in SLE patients. The pathogenic mechanism 
of lupus nephritis likely involves the deposition of immune complexes in the kidney and 
subsequent in situ activation of the complement system. Thus, measuring complement 
components and activation products in the plasma or urine may be useful for evaluating the 
extent of active inflammation in the kidneys.  These measurements may also be useful in SLE 
patients with CNS involvement, another serious, although less common, manifestation of SLE.  
Although a few studies have suggested that elevations in complement activation products are 
related to CNS involvement in SLE, further study is warranted. A summary of studies 
investigating complement measures in organ specific manifestations of SLE is depicted in Table 
1-3. 
Since SLE is a prototypic multi-organ autoimmune disease, one would expect 
measurements of complement in tissue fluid obtained from specific sites of inflammation to be 
informative. However, only a few, mostly anecdotal, studies have been performed to date 
examining complement levels in synovial fluid [27], pleural fluid [28,29], pericardial fluid [30,31], 
and cerebrospinal fluid [32-34]. These were primarily small studies and yielded variable results. 
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Thus, the value of complement levels in body fluids as indicators of specific organ involvement 
remains unclear. Systematic investigation in this area is warranted. 
 
1.3.4 COMPLEMENT AND PREGNANCY IN SLE 
A majority of SLE patients are women of childbearing potential; therefore, physicians treating 
pregnant SLE patients frequently face the dilemma of differentiating a disease flare from a 
pregnancy-associated complication. Renal involvement in SLE patients may be exacerbated at 
various stages of pregnancy.  If occurring in the third trimester, a nephritic flare may be difficult 
to distinguish from preeclampsia, a complication of pregnancy occurring most frequently at this 
stage, since the protenuria and hypertension associated with preeclampsia may mimic an SLE 
flare. It is extremely important to distinguish these two conditions because their management is 
quite different. Laboratory tests, such as complement measurements, have been employed in this 
regard; however, they should be interpreted cautiously since the physiological changes 
associated with pregnancy vary widely. For example, it has been shown that during the 
gestational period in a normal pregnancy, serum levels of C3, C4, and CH50 gradually increase 
from 10% to 50% above non-pregnant levels [35-37]. Such increases may counterbalance the 
consumption of complement during an SLE flare, making the C3 and C4 levels appear normal in 
a pregnant SLE patient with more severe disease. Conversely, decreased serum C3, C4, and 
CH50 have been observed in a fraction of pregnant women with SLE not experiencing a disease 
flare [36]. The depressed complement profile in these women could be mistakenly attributed to 
an SLE flare when in fact preeclampsia is present.  
Table 1-6 represents the results of several studies examining complement in pregnancy. 
In general, CH50 appears to be a key determinant in differentiating SLE flares from preeclampsia 
[38]. Moreover, increased plasma concentrations of Ba and Bb appear to be highly specific 
(specificity 100% and 75%, respectively), sensitive (sensitivity 100% for both), and predictive of 
a disease flare in pregnant SLE patients [38,39]. In terms of diagnosing a flare, conventional 
measures of serum C3 and C4 were neither sensitive nor specific [38]. Therefore, it appears that 
the laboratory tests of choice in such a diagnostic and therapeutic dilemma concerning pregnant 
SLE patients should be a combination of measures of CH50 and plasma concentrations of 
complement activation products, particularly Ba and Bb. 
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 1.3.5 A NOVEL ERYTHROCYTE-BOUND COMPLEMENT ASSAY – A PATH TO THE FUTURE  
1.3.5.1 Complement and erythrocytes 
Most complement activation products have a short half-life and likely are cleared from the 
plasma and other tissue fluid in an efficient manner. These variables may contribute to the 
inconsistent reports regarding the correlation between levels of complement activation products 
and clinical disease activity. Complement proteins are abundant in the circulation and can readily 
interact with cells circulating in blood. Complement products covalently bound on cellular 
components likely last longer in circulation and hence may be detected more reliably.  In fact, 
isoforms of the complement C4d fragment have been identified as two minor blood group 
antigens, Rodgers and Chido, on erythrocytes of apparently healthy individuals [40-42]. In 
general, the amount of C4 on the surface of erythrocytes of healthy individuals is low but 
somewhat variable. These findings indicate that that complement C4 and particularly its stable 
end product of activation, C4d, can bind to and persist on erythrocytes of normal individuals. 
The mechanisms of the deposition of C4 on erythrocytes, however, are not well understood.  
Erythrocytes are the most abundant circulating blood cells and have easy access to 
products of systemic as well as localized inflammation.  Therefore, we hypothesized that they 
may serve as biological beacons of the in vivo inflammatory state and of disease activity in SLE 
patients and those with other inflammatory diseases. It should be pointed out that few, if any, 
studies investigating the presence of C4 and C4-derived activation products on erythrocytes of 
patients with inflammatory diseases have been conducted [41,43,44]. Accordingly, the 
mechanism and pathophysiological significance of the binding of C4 to erythrocytes in disease 
are largely unknown. Because such information may potentially be important not only to 
accurately diagnose and monitor disease activity but also to better understand the molecular 
pathogenesis of SLE, we decided to investigate whether erythrocytes from patients with SLE 
bear specifically abnormal levels of complement activation product C4d. In view of the 
involvement of erythrocyte-expressed complement receptor 1 (CR1) in the clearance of 
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complement-bearing immune complexes, we also explored the possibility that SLE-specific 
defects may be reflected by abnormal CR1 levels on erythrocytes.   
 
1.3.6 ERYTHROCYTE-BOUND C4D AND SLE 
To test the above-stated hypothesis, we developed a flow cytometric assay in our laboratory to 
rigorously measure the levels of C4d and CR1 on the surface of erythrocytes. We conducted a 
cross-sectional study that included 100 patients who met the American College of Rheumatology 
criteria for the diagnosis of SLE, 133 patients with other diseases, and 84 healthy controls (Manzi 
et al., in press). Several remarkable findings have emerged from this study. First, significantly 
higher C4d levels were detected on erythrocytes of SLE patients than on those of patients with 
other diseases or healthy individuals (P<0.001). Second, high C4d levels on erythrocytes appeared 
to be specifically associated with SLE but not other inflammatory diseases (P<0.001). Third, CR1 
levels were significantly lower in SLE patients than in patients with other diseases or in healthy 
controls (P<0.001). Fourth, the erythrocyte-C4d/CR1 (E-C4d/CR1) test was 81% sensitive and 
91% specific in distinguishing SLE patients from healthy controls, and 72% sensitive and 79% 
specific in distinguishing patients with SLE from patients with other diseases, and an overall 
negative predictive value of 92%. This study demonstrated for the first time, in a systematic 
fashion, that considerable amounts of a complement activation product are present on the surface of 
erythrocytes in patients with an inflammatory disease such as SLE. In addition, the results obtained 
from this study are consistent with previous studies showing that decreased levels of CR1 on 
erythrocytes may be a general feature in SLE [45,46]. More importantly, this study demonstrated 
that measurement of E-C4d and E-CR1 is a simple, rapid, and inexpensive method that has greater 
combined sensitivity and specificity than any currently available tests for diagnosing SLE. This 
assay should ultimately have significant impact on the accuracy and timing of SLE  diagnosis in 
general clinical practice, and may lead to earlier and more appropriate therapeutic interventions. 
Of even greater value would be the ability of this assay to quantitatively detect ongoing 
disease activity in an SLE patient at a specific point of time. In this regard, we have found that E-
C4d levels detected on erythrocytes of healthy controls were remarkable constant over days, weeks, 
and even months within a given individual (Manzi et al., in press), suggesting that even slight 
fluctuations in E-C4d levels may reflect changes in complement activation. Interestingly, in 
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contrast to the constant E-C4d levels observed in healthy individuals, the E-C4d levels in the same 
SLE patient examined on different study visits varied considerably (Manzi et al., manuscript in 
preparation). We have postulated that E-C4d levels may correlate with the extent of complement 
activation and SLE disease activity in a quantitative manner, rendering them not only a specific 
diagnostic aid but also a sensitive indicator of evolving SLE disease activity. A prospective study is 
currently underway to verify this hypothesis. If validated, this assay may prove to be superior to 
current standard tests, such as anti-dsDNA and serum C3 and C4, for diagnosis, assessment of 
disease activity, and prediction of disease flares in patients with SLE.  
 
1.3.7 PERSPECTIVES - THE FUTURE 
A wide variety of biological molecules have been investigated as potential biomarkers of disease 
activity in SLE. The search for complement-unrelated surrogate markers, such as anti-dsDNA, 
cytokines, soluble cytokine receptors, and soluble cell adhesion molecules, has been propelled in 
part by the unsatisfactory results of complement measures. In spite of intensive studies, however, 
the value of most of these molecules is still questionable, and most of the tests are not generally 
applicable in routine clinical settings. Our recent study of erythrocyte-bound complement in SLE as 
an accurate and timely diagnostic tool will undoubtedly rekindle enthusiasm for complement not 
only in the clinical management of SLE but also in complement biology. 
Enthusiasm for the newly developed E-C4d/E-CR1 assay stems from its many advantages 
over current methodology. Obvious advantages include its simplicity, applicability, accuracy, and 
cost-effectiveness. Less obviously but more importantly, this assay measures complement products 
that associate stably with erythrocytes for a long period of time, in striking contrast to conventional 
assays that measure soluble complement components and their highly unstable activation products. 
Consequently, measurement of E-C4d is expected to mirror sensitively and faithfully, in a 
quantitative way, the degrees of complement activation and hence the disease activity in patients 
with SLE. This is an unsurpassed feature of the E-C4d assay compared to conventional 
complement measures. Furthermore, because complement products, once generated, probably 
remain bound to erythrocytes for the entire lifespan of those cells, E-C4d levels detected on a given 
day may reveal not only the ongoing disease activity but also the cumulative activity of the 
preceding days. In this context, the E-C4d assay is invaluable because it provides physicians with 
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power to promptly diagnose SLE, carefully assess current as well as recent disease activity, 
institute needed treatment, and accordingly terminate unnecessary interventions. Prospective 
studies underway in our laboratory will attest to this potential of the E-C4d assay. 
There are additional, yet-to-be-validated uses of the E-C4d assay. For example, 
measurement of E-C4d may assist in identifying SLE patients with hematological manifestations 
including impending attack of hemolytic anemia. Because it appears to be more sensitive and 
specific than conventional complement assays, E-C4d measurement may also allow identification 
of SLE patients with “smoldering” disease activity and timely installation of preventive 
interventions. These features of the E-C4d assay, nevertheless, await further investigation. 
In summary, we see that in the past, complement had a promising future as a valuable 
biomarker of SLE disease activity, but in reality has been a disappointment.   The role of 
complement may soon be vindicated, however, as new discoveries of the utility of erythrocyte-
bound complement as a novel diagnostic tool in SLE may translate to its unsurpassed value as an 
indicator, and possibly predictor, of SLE disease activity. Realization of this potential hinges on 
large-scale cross-sectional as well as long-term prospective studies that demand coordinated 
efforts from both investigators and physicians. With the intensive research ongoing in our and 
other laboratories, the comeback of complement as a valuable disease biomarker should occur in 
the foreseeable future. 
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Table 1-1. Selected Studies Investigating the Value of Serum Complement Measures in SLE 
Study Study Design Results/Conclusions 
Lloyd and Schur 
[47] 
Prospective study following 27 SLE patients 
through 47 cycles of clinical activity; Serological 
tests: CH50, C1q, C3, C4, anti-dsDNA, and 
immune complex (C1q binding activity) levels; 
Disease activity: physician assessment  
CH50, C3, C4 levels lower in patients with 
active renal disease than in patients with 
extra-renal involvement; Decreasing C4 
levels proceeded disease flares 
Valentijin et al. 
[48] 
Retrospective study using serial serum samples 
obtained from 33 SLE patients; Serological test: 
CH50, C3, C4, immune complexes (C1q binding); 
Disease activity: scoring system designed by 
authors  
Significant correlation between overall 
disease activity, decreased C3/CH50, and 
increased immune complex levels; Low 
sensitivity, specificity, and predictive value; 
Correlation between C3/C4 levels and 
organ involvement in subgroups of patients  
Ricker et al. and 
the Lupus 
Nephritis 
Collaborative 
Study Group 
(LNCSG) [49] 
Retrospective study using serial serum samples 
obtained from 12 SLE patients with severe 
nephritis; Serological tests: C3, C4; Disease 
activity: definitions set by the LNCSG 
Normal C3 levels observed during disease 
remission; Abnormal C3 levels more 
frequently detected during flares than C4; 
Higher specificity and sensitivity of C3 than 
C4 in monitoring SLE disease activity  
Mills et al. [50] Prospective study of 29 SLE patients; Serological 
tests: C1q, c4, C4a, C2, C3, C3a, C5, CH50, 
C4a:C4 ratio, C3:C3a ratio; Disease activity: 
clinical and serological assessment 
Reduced C2 and C3 levels distinguishing 
patients with active disease from those with 
inactive disease; C1q, C4, C5, and CH50 
less useful 
Cameron et al. 
[51] 
Prospective study following 99 SLE patients; 
Serological tests: C3, C4, anti-dsDNA; Disease 
activity: a 7-point scoring system 
No correlation between C3 levels and 
disease activity; Decreased C4 levels 
detected in both patients with active and 
inactive disease; Normal C4 not found in 
patients with active disease  
Swakk et al. [52] Prospective study of 143 patients; Serological 
tests: C1q, C3, C4, C5, C9, anti-dsDNA:  
Decreased C4, C1q, and C3, in a sequential 
order, detected in patients with renal 
exacerbation; Decreasing C4 detectable 20-
25 weeks before the flare; Decreased C1q 
and C3 detected during but not before the 
flare   
Ting and Hsieh 
[53] 
Long term study of 16 patients with childhood 
onset SLE; Serological tests: C3, C4, ANA, anti-
dsDNA; Disease activity: Lupus activity criteria 
count (LACC) 
Decreased C3 levels detected during, but 
rarely before, the active stage of disease; 
Decreased C4 levels detected prior and 
during active disease 
Abrass et al. [54] Prospective study following 48 SLE patients; 
Serological tests: C3, anti-dsDNA, immune 
complexes; Disease activity: clinical record of 
disease manifestations and medications 
C3 and anti-dsDNA neither associated with 
nor predictive of changes in disease activity 
Morrow et al. 
[55] 
Prospective follow up of 35 SLE patients; 
Serological tests: CH50, C3, C4, anti-dsDNA, 
immune complexes; Disease activity: graded as 
severely active, moderately active, and inactive 
using the UCH/Middlesex criteria 
None of the serological tests reliably 
distinguishing the three clinical groups 
Esdaile et al. 
[56,57] 
Retrospective analysis of serum samples collected 
from 202 patients; Serological tests: C3, C4, anti-
dsDNA, immune complexes; Disease activity: 
SLEDAI, a rise of > or = 6 defined as a flare 
All serological parameters tested poor 
predictor of SLE flares; some values of 
patient-based serial measures in association 
with specific types of flares (e.g., decreased 
C3 and renal involvement) 
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Table 1-2. Select Studies Determining the Value of Complement Activation Products in SLE 
Complement 
activation product(s) 
tested 
Study Results/Conclusion 
C1rs-C1inh, C3d Sturfelt et al. [58] 
Serial (at 6-8 wk intervals) samples from 
33 SLE patients 
Increased C1rs-C1inh consistently found during 
flares; Increased C1rs-C1inh detected before 
flares, especially extra-renal flares; Increased 
C3d associated with severe disease flares  
Cirs-C1inh, C3(Bb)P, 
C5b-9 
Nagy et al. [59] 
Plasma samples obtained from healthy 
controls and  65 SLE patients with 
active and inactive disease  
All 3 activation products elevated in SLE 
patients with inactive disease compared to 
healthy controls; C3(Bb)P and C5b-9, but not 
C1rs-C1inh, distinguishing active disease from 
inactive disease 
C4a, C3a Wild et al. [60] 
Plasma samples of 24 SLE patients 
Elevated C4a levels detected in 20 patients; 
C4a levels correlated with disease activity; 
Elevated C3a levels found in 2 patients only 
C3a, C5a Belmont et al. [61] 
Plasma samples of 76 SLE patients with 
severe, moderate, or inactive disease 
C3a significantly elevated in patients with 
severe or moderate disease activity and 
quantitatively correlated with disease severity; 
C5a significantly elevated in patients with 
severe disease activity 
C3a, C5a Hopkins et al. [62] 
Serial plasma samples from 23 SLE 
patients (7 pregnant; 5 CNS 
involvement) 
C3a levels significantly higher in patients with a 
flare than in those with stable disease; 
Rising C3a levels predictive of disease flares; 
Highly elevated C3a and C5a in patients with 
CNS involvment; 
C3a levels elevated in most pregnant patients 
C3a, C4a, iC3b, C5b-9 Porcel et al. [63] 
Plasma samples of 61 SLE patients (22 
inactive disease; 39 active disease; 
defined by SLEDAI) 
C3a, C4a, and C5b-9 significantly elevated in 
patients with active disease, with a positive 
correlation with disease activity scores;  
C5b-9 being most sensitive and specific; 
iC3b not correlated with disease activity 
C4d, C3d Senaldi et al. [64] 
Plasma samples of 48 SLE patients (11 
inactive, 23 mildly active, 14 
moderately/severely active) 
Elevated C4d levels correlated with disease 
activity in a linear fashion;  
C3d levels elevated but not linearly correlated 
with disease activity 
Ba, Bb, C4a, C3d Kerr et al. [65] 
2-year follow-up of 51 SLE patients 
Increase of  Ba, C4a, and C3d in the same 
patients associated with severe disease activity 
Ba, Bb, C4d, C5b-9 Buyon et al. [38] 
380 serial plasma samples from 86 SLE 
patients with inactive, stable/moderate, 
or severe disease 
Ba levels significantly elevated and positively 
correlated with disease activity; 
Elevated C4 and increased Bb predictive of 
subsequent flares 
Bb, C4d, C5b-9 Manzi et al. [66] 
21 SLE patients prospectively followed 
for 1 year  
C4d and Bb sensitive indicator of moderate-to-
severe disease activity; 
 C4d and Bb sensitive at predicting increasing 
disease activity 
C5b-9 Falk et al. [67] 
108 serial plasma samples from 14 SLE 
patients 
C5b-9 levels significantly elevated in SLE 
patients, and positively correlated with disease 
activity 
C5b-9 Gawryl et al. [68] 
120 plasma samples from 28 SLE 
patients 
Elevated C5b-9 levels correlated with disease 
exacerbation; C5b-9 a more sensitive marker of 
disease marker than C3 and C4 
 15
Table 1-3. Select Studies on Complement Measures in Organ Specific Manifestations of SLE/in Different 
Body Fluids 
Study Study Design Results/Conclusions 
Renal Manifestations 
Lloyd et al. 
[47] 
Prospective study of 27 SLE patients, 
with and without renal 
manifestations; Serological tests: 
C1q, C3, C4; SLE activity: clinical 
and serological assessment 
SLE patients with renal involvement have reduced serum C3 
and C4 more frequently than patients with extra-renal 
involvement only; nevertheless, the lowest levels of C3 and C4 
are detected in patients with both renal and extra-renal disease. 
Low levels of C1q are in patients with active renal disease 
Valentijn et 
al. [48] 
Longitudinal study of 33 female 
patients with SLE; Serological tests: 
CH50, C3, C4 SLE activity: clinical 
and serological assessment 
Mean C3 and CH50 levels are significantly lower in patients 
with active renal disease than when renal involvement is absent. 
The mean level of C4 is slightly lower during active renal 
disease than during inactivity 
Pillemer et 
al. [69] 
Longitudinal study of 55 patients 
with lupus nephritis; Serological test: 
C3; Activity of lupus nephritis: 
scoring system designed by authors 
Low C3 are associated with increased renal biopsy scores for 
cellular crescents, necrosis and endocapillary proliferation; 
Higher renal chronicity index is associated with longer duration 
of abnormal C3; Depressed C3 predicts the extent of 
persistently active glomerular disease in lupus nephritis 
Manger et 
al. [70] 
Prospective study of 338 SLE 
patients; Serological tests: C3, C4; 
SLE activity: ECLAM, SDI 
Low C3 at disease onset is a significant risk factor for 
subsequent end stage renal disease 
Gunnarsson 
et al. [71] 
Prospective study of 18 SLE patients 
with proliferative nephritis; 
Serological tests: C3, C4, C1q; 
Disease activity: clinical and 
serological assessment 
At first biopsy, low C1q is found; At repeated biopsy, low C1q 
combined with albuminuria predicts persistent histopathological 
activity. So serum C1q levels at both first and repeated renal 
biopsies are predictive marker of the histopathological outcome 
Sturfelt et al. 
[58] 
Prospective study of 33 patients with 
SLE; Serological tests: C1q, C3, C4, 
C3d; SLE activity: clinical and 
serological assessment 
C3d is consistently elevated during active glomerulonephritis; 
Persistently increased C3d predicts subsequent renal failure; 
C1q levels are transiently low during flare-ups of lupus 
glomerulonephritis 
Perrin et al. 
[72] 
41 SLE patients; 31 cases of 
membranoproliferative glomerulo- 
nephritis (MPGN); 26 other types of 
GN cases, 6 cases of severe alcoholic 
cirrhosis of the liver; Serological 
tests: C3, C3d 
Elevated plasma C3d is found in 68% SLE cases, in 87% 
MPGN cases, in 62% patients with other hypocomplementic 
nephritis, but only in 15% patients with normocomplementic 
nephritis and in 33% patients with liver cirrhosis; Inverse 
correlation between C3d levels and levels of C3 in plasma 
Negi et al. 
[73] 
24 SLE patients (8 inactive disease 
cases, 7 active non-renal disease 
cases, 9 active lupus nephritis), 15 
healthy individuals; Tests: c3, C4, 
C3d (serum and urine); SLE activity: 
SLEDAI 
Serum C3d is higher in lupus patients than in healthy controls; 
Serum C3d levels are comparable in active renal and extrarenal 
SLE; Urine C3d is elevated only in active SLE, with highest 
levels in active lupus nephritis; Urine C3d is in stronger 
correlation with SLEDAI than serum C3, C4, C3d 
Kelly et al. 
[74] 
Prospective study of 28 SLE 
patients; Tests: plasma C3, C4, C4d, 
Bb, C5b-9, urine C3d; SLE activity: 
SLAM, SLEDAI, PGA  
Patients with normal C3 patterns had minimal disease activity; 
Patients with low molecular weight C3 fragments in urine had 
either severe disease with active lupus nephritis, or non-renal 
SLE of moderate disease activity 
Manzi et al. 
[66] 
Prospective study of 31 SLE 
patients; Tests: plasma C3, C4, C4d, 
Bb, C5b-9, urine C3d; SLE activity: 
SLAM, SLEDAI, PGA 
Urine C3d is better than C3, plasma C4d, Bb, C5b-9 in 
distinguishing acute lupus nephritis patients from those without 
such disease activity 
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Table 1-4 (contd.) 
Study Study Design Results/Conclusions 
Hematological Manifestations 
Ho et al. 
[75] 
Prospective study of 53 SLE 
patients; Serological tests:  C3, C4; 
SLE activity: PGA, M-SLEDAI, 
SLAM, M-LAI, M-BILAG  
Decreases in C3 are associated with concurrent decreases in 
hematocrit, platelet, and white blood cell counts; Previous 
increases in C3 are associated with a decrease in platelets; 
Decreases in C4 are associated with concurrent decrease in the 
hematocrit level and platelet count; Decreases in complement 
levels are not consistently associated with SLE flares 
CNS Manifestations 
Hopkins et 
al. [62] 
Prospective study of 40 SLE 
patients; Serological tests: C3, C4, 
C3a, C5a; SLE activity: physician 
assessment 
Plasma C3a levels increase in SLE patients during a disease 
flare, and are particularly high in 5 patients who had acute CNS 
dysfunction. In 4 of these 5 patients, significantly elevated 
plasma C5a levels are also detected  
Rother et al. 
[76] 
79 SLE patients; Serological tests: 
C3, C4, CH50, C3d; SLE activity: 
M-LAI 
SLE patients with CNS involvement have significantly higher 
levels of plasma C3d than do patients without CNS involvement 
Karassa et 
al. [77] 
32 SLE patients with CNS events 
matched 1:3 to 96 control SLE 
patients without CNS events; 
Serological tests: C3, C4; SLE 
activity: clinical and serological 
assessment 
Low serum C3 and C4 levels are associated with CNS 
involvement; The odds for SLE patients with low serum C3 or 
C4 levels to have CNS disease are 3.8 (95%CI 1.6-9.4) and 3.5 
(95%CI 1.8-6.8), respectively, compared to those with normal 
C3 or C4 levels 
CNS Manifestations/Cerebrospinal Fluid 
Petz et al. 
[33] 
Cerebral spinal fluid  (CSF) samples 
from 11 SLE patients (4 subjects – 
multiple samples) and from 25 
healthy controls; serum samples from 
other 20 healthy controls; Tests: 
serum C1-C4, CH50, and C4 in CSF 
C4 levels in CSF are reduced in patients with active CNS SLE, 
and are at significant correlation with clinical manifestations of 
the disease. C2 and CH50 are also sensitive indicators of 
disease activity, whereas C3 is less frequently reduced  
Sanders et 
al. [34] 
CSF and serum samples from 
Sjogren’s syndrome (SS) patients 
and from SLE cases; Tests: C5b-9 in 
serum and CSF  
C5b-9 is detected in 86% SLE-CNS cases and in 88% SS-CNS 
cases. In some of them, C5b-9 is present in CSF, but not serum. 
It is suggested that the terminal pathway of complement is 
activated intrathecally in patients with CNS in both SLE and SS  
Jongen et al. 
[32] 
12 SLE patients with diffuse CNS 
and 28 control subjects; Tests: SCF 
and serum C3, C4 
In CNS SLE, serum C4 is reduced, which reflects low-grade 
systemic disease activity, and C3, C4 CSF/serum ratios are 
increased, which reflects compensatory intrathecal production. 
This indicates that CSF/serum ratio is a valid tool to detect 
intrathecal C3 or C4 production  
Arthritis Manifestations/Synovial fluid 
Ropes and 
Bauer        
(1 suppl) 
20 synovial fluids form 11 SLE 
patients; Tests: white blood cell 
counts, protein concentrations 
Low white blood cell counts, low protein concentrations 
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Table 1-5 (contd.) 
Study Study Design Results/Conclusions 
Hedberg     
(2 suppl) 
10 SLE patients (9 cases with 
arthritis duration >1 yr); Tests: 
complement levels, protein 
concentrations in synovial fluid 
Elevated protein concentrations; Low complements, with values 
approximating those of fluids from patients with rheumatoid 
arthritis  
Pekin et al. 
[27] 
26 SLE patients; Tests: white blood 
cells, protein, CH50 in synovial fluid 
and serum; SLE activity: clinical and 
serological assessment 
2 Classes of SLE effusions: 1) transudative (in acute SLE with 
low serum CH50, but without joint complaints): low CH50, low 
white blood cell count and protein in synovial fluid; 2) 
exudative (in active SLE with inflammatory polyarthritis): low 
CH50 despite large amounts of other serum proteins in the joint 
cavity. This indicates that low complement levels in joint fluids 
come through two distinct mechanisms 
Pleural Manifestations/Pleural fluid 
Hunder et al. 
[28] 
23 Subjects with malignant disease, 6 
SLE cases, 6 rheumatoid arthritis 
(RA) cases, 3 congestive heart failure 
cases, 3 pulmonary embolism cases, 
9 cases of pleural effusion of 
undefined cause; Tests: C3, C4, 
CH50 in pleural fluid 
Pleural fluid in SLE and RA contain significantly less CH50 
and C3, C4 than pleural fluid from patients with non-rheumatic 
diseases; Serum-to-pleural fluid complement concentration ratio 
is greater in SLE and RA than in non-rheumatic subjects. This 
indicates increased complement utilization in pleural fluid with 
a potential of pleuritis development in these patients  
Kinney et al. 
[29] 
Non-SLE subjects undergoing open-
heart surgery for coronary artery or 
rheumatic heart disease; Tests: C3, 
C4, CH50 in pericardial fluid 
Normal ranges for pericardial-fluid C3, C4 and CH50 are 35-
127 mg/dl, 6.3-23 mg/dl, 1.9-9.1 CH50 units, respectively 
   
Pericardial Manifestations/Pericardial fluid 
Goldenberg 
et al. [30] 
Series of samples from an SLE 
patient with a large pericardial 
effusion and from non-SLE control 
subjects undergoing heart surgery; 
Tests: CH50 in serum and pericardial 
fluid, ANA, anti-DNA 
No hemolytic complement activity is detectable in the SLE 
patient, whereas in controls CH50 is >25 units/ml. In SLE 
patient, pericardial fluid contains positive ANA and anti-DNA, 
and >90% neutrophils. This indicates a localized immune 
reaction within the pericardium space in SLE patients 
Hunder et al. 
[31] 
2 SLE patients with pericarditis and 
2 non-SLE controls with valvular 
heart disease; Tests: CH50, C1q, C3, 
C4 in serum and pericardial fluid 
In Patient 1, the pericardial C3 is found to be half that of serum; 
pericardial C1q and C4 are also low, CH50 is absent. In Patient 
2, CH50 is also absent, even though serum CH50 is normal, and 
all the complement components are similar to those in controls. 
Activation of both classical and alternative pathways is 
suggested in pericardial fluid of SLE patients 
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 Table 1-6. Select Studies Investigating Complement Proteins in Pregnancy 
Study Study Design Results/Conclusions 
Baines et 
al. 
[35] 
Prospective study using serial serum 
samples obtained from 50 pregnant non-
SLE subjects and 116 normal 
nonpregnant controls; Serological tests: 
CH50, C3 
Gradually increasing C3 activity with pregnancy progression, 
following a significant depression during the 1st trimester, and 
slight though significant increases in the activity of CH50 
Gallery et 
al. [37] 
Prospective study of 173 initially 
normotensive pregnant non-SLE subjects 
and 32 non-pregnant controls; 
Serological tests: C3, C4  
Significant elevation of C3 and C4 during gestation; 
Hypertension in the 3rd trimester in 26 pregnant women, but 
with the same degree of C3 and C4 elevation as in the 147 
normotensive pregnant subjects. So C3 and C4 tests are of no 
value in prediction of pregnancy-associated hypertension 
Buyon et 
al. [36] 
Prospective study of 12 pregnant SLE 
patients, 17 non-SLE preeclampsia 
subjects, 24 normal pregnant subjects, 
and 21 healthy nonpregnant controls; 
Serological tests: C3, C4; SLE activity: 
clinical and serological assessment 
Elevated C3 and C4 in normal pregnancy; In non-SLE 
preeclampsia, C3 levels same as in normal pregnancy, and 
decreased C4; In SLE pregnancy, C3 and C4 lower than in 
normal pregnancy or preeclampsia; In SLE pregnancy, falling 
C3 or C4 predicted a flare; Preeclampsia in some of the SLE 
cases with rising C3, but not SLE flare. So C3 and C4 can 
distinguish between SLE flare and preeclampsia.  
Hopkinso
n et al. 
[78] 
Cross-sectional study of 83 pregnant 
women and 80 controls (47 men and 33 
non-pregnant women); Serological tests: 
C3, C4 and C4d  
Significantly elevated C3, reduced C4, increased C4d and 
higher C4d:C4 ratio in pregnant women. So plasma C4d 
cannot be used as a marker of diseases activity in pregnant 
patients with connective tissue diseases as pregnancy itself 
leads to C4 activation 
Abramson 
et al. [39] 
A review article: serological markers used to differentiate SLE flare from diseases of pregnancy 
Teisner et 
al. [79] 
Prospective study of normal pregnant 
patients; Serological tests: C3, C4, C3c, 
C3d  
Increased levels of C3 and C3d in the 2nd and 3rd trimesters; 
C4 not affected by pregnancy; C3c not detected. Suggested 
increased turnover of native C3 during pregnancy rather than 
activation of the complement cascade 
Schena et 
al. [80] 
Prospective study of 286 normal pregnant 
women and 30 women with 
preeclampsia; Serological tests: CCH50, 
C3, C5, C9, C1inh, C1s, C1q 
Increase in levels of immune complexes associated with the 
exacerbation of the pre-eclamptic picture and a decrease after 
delivery. No significant difference between complement 
components it the 3rd trimester and in preeclampsia. High 
levels of C3d were observed in normal pregnancy and in 
preeclampsia 
Jenkins et 
al. [81] 
Cross-sectional study of 65 normal 
pregnant women and 39 controls (21 
non-pregnant women and 18 men); 
Serological tests: C3d 
No significant difference between the 2 groups; Similar C3d 
concentrations in all 3 trimesters. So C3d levels are 
unaffected by uncomplicated pregnancy and can be used to 
monitor complement activation in lupus irrespective of 
pregnancy 
Thomson 
et al. [82] 
Prospective study of 5 women with 
severe preeclampsia; 9 women with mild 
preeclampsia; 8 women with normal 
pregnancy; Serological tests: C3, C4, 
C1q  
No significant difference in complement components bw the 
3 groups 
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Table 1-4 (contd.) 
Study Study Design Results/Conclusions 
Hopkins et 
al. [62] 
Prospective study of 7 pregnant SLE 
patients, 16 pregnant healthy controls and 
7 non-SLE subjects with preeclampsia; 
Serological tests: C3, C4, C3a, C5a; SLE 
activity: physician assessment 
High normal C3 in healthy pregnant subjects and non-SLE 
preeclampsia; Normal C3 and elevated C3a in pregnant SLE; 
Inverse correlation bw C3decreases and elevations in C3a 
over time in pregnant SLE patients. Low C3 and associated 
increase in split products in pregnant SLE subjects indicate 
the complement activation 
Buyon et 
al. [38] 
Prospective study of 14 pregnant SLE 
patients and 10 non-SLE women with 
preeclampsia; Serological tests: C3, C4, 
CH50, Ba, Bb, SC5b-9, C4d; SLE 
activity: clinical and serological 
assessment 
During SLE flare - abnormal Ba, Bb, SC5b-9, CH50, but not 
C4d levels; In non-SLE preeclampsia with elevated Ba – 
normal CH50; Ratio CH50:Ba significantly lower in lupus 
flares than in non-SLE patients with preeclampsia. Ongoing 
activation of the alternative complement pathway can 
accompany SLE flares in pregnant patients 
Lockshin 
et al. [83] 
Prospective study of 28 SLE pregnancies; 
pregnant patients with non-SLE 
rheumatic disease; nonpregnant SLE; 
Serological tests: C3, C4, CH50, C1s-
C1inh; SLE activity: clinical and 
serological assessment 
Low complements in pregnant patients; Low CH50 and 
normal C1s-C1inh in pregnant patients; In pregnant SLE 
patients C1s-C1inh independent of CH50; In nonpregnant 
patients – linear relationship bw C1s-C1inh and CH50. 
Hypocomplementia occurs via different mechanisms in 
pregnant and nonpregnant patients with SLE 
Lao et al. 
[84] 
Prospective study of SLE patients in 
remission before pregnancy; Serological 
test: serum urate levels and serum C3; 
SLE activity: clinical and serological 
assessment 
Pregnant SLE patients who developed preeclampsia had a 
significantly higher serum urate level while their serum C3 
levels remained similar to those of patients without 
preeclampsia 
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2 Cost Effectiveness Analysis of the Novel Screen Test for the 
Diagnosis of Systemic Lupus Erythematosus 
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 2.1 INTRODUCTION 
Systemic Lupus Erythematosus (SLE) is an autoimmune chronic disease very difficult to 
diagnose. At present, the diagnosis is often late: at the moment of diagnosis nearly 80% of the 
patients show major organ involvement due to the disease activity [85]. For improved prognosis 
and prolonged survival in SLE patients, it is necessary to shift diagnosis closer to the time of 
actual disease onset.  
Timely diagnosis will also help to avoid aggressive treatment and complications from 
such treatment, and decrease healthcare costs [86]. It is not uncommon for rheumatologists to 
initiate treatment in patients who are thought to have lupus-like illness but do not meet the 
diagnostic criteria. To conclude that a patient has lupus without enough clinical and laboratory 
evidence can be detrimental both for the patient and physician, particularly if a mild form of 
lupus, is not distinguished from severe lupus. In addition to physiological effect, this can cause 
use of inadequate and potentially toxic therapies.  
Therefore, a reliable screening test for diagnosis of lupus is needed. In routine practice, 
physicians currently rely on single or multiple serologic abnormalities to differentiate lupus, 
such as antinuclear antibody (ANA), antibodies to dsDNA, anti-Smith antibody, and 
complement proteins C3 and C4. However, there is no single adequate marker among these 
abnormalities that is both sensitive and specific. The most commonly used the ANA test, 
provides at least 95% sensitivity, but only 49% specificity [87]. Detection of high titer antibodies 
to dsDNA, on the contrary, is very specific (96.6%), but not sensitive (58.1%)  and relatively 
expensive [88].  
A novel method for SLE diagnosis has recently been developed and is based on 
measuring complement activation. It is a simple, rapid, and inexpensive method that has greater 
combined sensitivity and specificity than any currently available tests for diagnosing SLE. This 
assay (the RBC test) can provide added value to traditional diagnostic tests for antinuclear 
antibodies (the ANA test) and anti-dsDNA antibodies (the DNA test) by capturing additional 
SLE patients among dsDNA false negatives and by avoiding inappropriate SLE diagnosis among 
ANA false positives.  
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The RBC is 81% sensitive and 91% specific for SLE versus healthy controls, and 72% 
sensitive and 79% specific for SLE versus other diseases, and it has an overall negative 
predictive value of 92%.This assay should ultimately have significant impact on the accuracy and 
timing of SLE diagnosis in general clinical practice, and may lead to earlier and more appropriate 
therapeutic interventions.  
The objective of the present study is to evaluate this new diagnostic marker from the 
health policy standpoint, combining clinical and economical data and testing whether a new 
diagnostic strategy using the new assay is more cost effective relative to existing diagnostic 
practices. 
 
2.2 METHODS 
2.2.1 DECISION PROBLEM 
To identify the costs and effects of different screening strategies involving the RBC and current 
standard ANA and DNA tests. This analysis assumes that the RBC test will not replace the latter 
two, but will complement them to enhance the diagnosis of lupus. 
2.2.2 TARGET POPULATION  
Several screening strategies are examined in a target population of white female subjects aged 
15-50 years, who have clinical symptoms of undefined connective tissue disease (UCTD).  
2.2.3 TESTING STRATEGIES 
The conventional test strategy for SLE consists of two tests: ANA and DNA, where ANA is 
followed by DNA in the case of positive result of the former test.  
The introduction of the new RBC test may improve the overall testing performance in 
terms of detecting patients with high post-test probability of having disease.  
We intend to design an optimal testing strategy that would include traditional tests ANA 
and DNA, and the new test RBC. 
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Parameters of the tests such as sensitivity, specificity and the costs of performing the 
tests are presented in Table 2-1.  
Table 2-1. Parameters of SLE tests: ANA, DNA, and RBC 
Tests Sensitivity Specificity Cost 
ANA 0.95 0.49 38 
DNA 0.581 0.966 108.25 
RBC 0.86 0.71 56.57 
 
If all three tests are performed consecutively, they give eight possible testing outcomes 
with different post-test disease probabilities (please refer to  ). The post-test probabilities are the 
functions of pre-test probability of disease in population of interest and the sensitivity and 
specificity parameters of the tests involved. The post-test probability of the disease after a 
positive test is calculated as: 
 
 ( )( )1 1pretestposttest pretest pretest
p sens
p
p sens p spec
⋅= ⋅ + − −  
 
The post-test probability of the disease after negative test is: 
 
( )
( ) ( )
1
1 1
pretest
posttest
pretest pretest
p sens
p
p sens p spec
⋅ −= ⋅ − + − , 
where 
 
- post-test probabiltiy of disease
- pre-test probability of disease
 - test sensitivity
 - test specificity
posttest
pretest
p
p
sens
spec
 
 
2.2.4 STUDY QUESTIONS 
1. To evaluate additional costs and effectiveness associated with adding the RBC test to the 
traditional testing strategy. 
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2. To identify the least cost method of use of the RBC test. 
 
2.2.5 MARKOV MODEL 
Markov (state transition) models are used in this analysis to compare costs and health effects 
incurred as a result of diagnostic strategies involving the RBC test and the traditional strategy 
(ANA test followed by DNA) over a 10-year timeframe with the 1-year cycle length. The 
evaluation is performed from the societal perspective.  
No SLE
SLE
Death
Screening 2
Screening 1
No SLE
SLE
SLE
Death
Death
 
Figure 2-1. General comparison model 
2.2.6 DATA ELEMENTS IN MARKOV MODELS 
Table 2-2 lists the parameters and their values used in the Markov models. The explanations of 
the values follow below.  
Incidence of SLE. Since our target population consists of women coming to a 
rheumatologist’s office with symptoms of undefined connective tissue disease (UCTD), the 
incidence is estimated to be 0.0051.  
                                                 
1 Personal communication with S. Manzi, MD, MPH, March 2004 
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Prevalence of SLE. Since our target population consists of women coming to a 
rheumatologist’s office with symptoms of undefined connective tissue disease (UCTD), the 
prevalence is estimated to be 0.0051.  
Probability of dying from SLE. Source: Trends in Deaths from Systemic Lupus 
Erythematosus – United States, 1979-1998 [89]. 
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5117a3.htm 
 
Table 2-2. Data elements used in the analyses 
Variables Values 
Incidence of SLE, per person 10/1,000 
Prevalence of SLE 2/1,000 
Probability of dying from SLE 0.0011 
Probability of dying from SLE under early diagnosis 0.0001 
Probability of dying from causes other than SLE 0.0072 
Utility for having no SLE 0.9 
Utility for having SLE 0.62 
Utility for having early-detected SLE 0.73 
Utility for toxicity of unnecessary treatment 0.84 
Sensitivity of RBC test 0.720 
Specificity of RBC test 0.790 
Sensitivity of ANA test 0.950 
Specificity of ANA test 0.490 
Sensitivity of dsDNA test 0.581 
Specificity of dsDNA test 0.966 
Cost of RBC test 56.57 
Cost of ANA test 38.00 
Cost of dsDNA test 108.25 
Expected annual cost of illness in SLE 12,364.06 
Expected annual cost of early-detected SLE 9,697.34 
Expected annual cost associated with side effects of unnecessary 
treatment 137.56 
Expected annual cost associated with prophylactic treatment 808.26 
 
Probability of dying from SLE under early diagnosis. The factor most closely related 
to mortality in SLE is exacerbation frequency [85]. Patients fulfilling less of the SLE criteria at 
the time of diagnosis are less prone to exacerbations in future course of the disease [90]. It is 
assumed that early diagnosis before the development of required four criteria and early onset of 
treatment will avoid exacerbations and ensure 10-year survival close to 100% [85]. We therefore 
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expect very low mortality in SLE patients diagnosed early, and estimate it to the 0.0001 per 
person.  
Probability of dying from causes other than SLE. Source: age-adjusted death rates for 
white and black females from the National Vital Statistics Report. 
http://www.cdc.gov/nchs/data/nvsr/nvsr50/nvsr50_15.pdf  
Utility for having no SLE. Based on the modified HUI3 (mHUI3) and assumed to be 
similar to “very good” self-rated health [91].  
Utility for toxicity of unnecessary treatment. Based on the modified HUI3 (mHUI3) 
and assumed to be similar to “good” self-rated health [91].  
Utility for having early-detected SLE. Based on the modified HUI3 (mHUI3) and 
assumed to be equal to the average between “fair” and “good” self-rated health [91]. 
Utility for having SLE. Based on the modified HUI3 (mHUI3) and assumed to be 
similar to “fair” self-rated health [91].   
Sensitivity and specificity of RBC test. Source: Manzi S. et al., 2002 [92]. 
Sensitivity and specificity of ANA test. Source: Tan E. et al. 1982 [87]. 
Sensitivity and specificity of dsDNA test. Source: Servais G. et al. 2001 [88].  
Cost of RBC test. Preliminary estimation done in the Lupus Center of Excellence, 
University of Pittsburgh, 2003. 
Cost of ANA and dsDNA. Source: CPT code book; assumption: the tests are done at the 
Immunology department of the University of Pittsburgh Medical Center (UPMC). 
Expected annual cost of illness in SLE. Source: Sutcliffe N. 2001. Both direct and 
indirect costs are included [86].  
Expected annual cost of early-detected SLE. Source: Sutcliffe N. et al, 2001 [86]. The 
mean SLICC index reflecting cumulative organ damage is found to be 1.1 for a cohort with mean 
age of 40 and disease duration 10.5 years, and according to the regression results of the same 
study, 1 unit increase in SLICC is associated with $2,666.72 increase in total cost of disease. It 
was found that the rate of damage increase is most pronounced during the first year after dx 
[93,94]. So, if we diagnose and start controlling the disease earlier, we can hope to prevent organ 
damage (expressed as preventing SLICC index from increasing to >0.1). This will decrease the 
cost by $2,666.72, and the annual cost of SLE under early dx and treatment will be $9,697.344. 
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Expected annual cost associated with side effects of unnecessary treatment. Source: 
Bae, S. et al., 2003 [95]. We assume that for SLE patients, cost due to treatment toxicity is 
already incorporated into the cost of illness. However, for false positive, the cost associated with 
side effects of unnecessary treatment should specifically be taken into account.  
2.2.7 ANALYTIC PLAN 
2.2.7.1 Analysis 1.  
“Simple” comparison”: we will evaluate incremental cost and effectiveness of simply adding the 
RBC test to the traditional strategy for subjects whose ANA is positive, but DNA is negative. 
We assume that this can decrease the number of false DNA negatives who need the treatment but 
will not be treated according to testing results (Figure 2-2).  
No SLE
SLE
Death2. ANA, DNA
1. ANA, DNA, RBC
No SLE
SLE
SLE
Death
Death
Death
DNA neg
DNA pos
ANA pos
ANA neg
ANA pos
ANA neg
DNA neg
DNA pos
RBC neg
RBC pos
 
Figure 2-2. “Simple” comparison: traditional strategy vs. strategy involving the RBC test 
 
However, it is possible that the negative effect of treating the RBC false positives outweighs the 
positive effect of subjecting the RBC true positives to necessary treatment with steroids. In this 
case, the decision to treat the RBC positives results in reduction in expected years of life, which 
would not be an appropriate health policy action. 
 
In order for the treatment decision always to increase the expected years of life, it should be 
taken only when the probability of the disease after the series of test results exceeds a certain 
threshold. So the next step in the analytic plan is: 
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2.2.7.2 Analysis 2  
To determine the therapeutic threshold at which SLE prophylactic treatment should be applied. It 
is assumed that if the posttest probability of having the disease exceeds a pre-specified 
therapeutic threshold, patients will thereafter be closely observed by a rheumatologist specialist 
and administered certain treatment such as low-dose steroids or NSAIDs, to avoid development 
of more lupus criteria and worsening of the disease.  
An exploratory analysis is conducted to identify the potential application of the RBC test in 
various possible strategies. The diagnostic strategies involving RBC are developed as described 
below, based on the therapeutic threshold. 
2.2.8 THERAPEUTIC THRESHOLD CALCULATION 
The success of the screening tests in the Analysis 2 is based on the ability to detect lupus at a 
probability at which application of therapy becomes reasonable (therapeutic threshold). That is, 
if the therapy is applied, its expected positive effect in a patient who has disease outweighs the 
expected negative effect of therapy in a patient who does not have disease [96]. 
We determine the therapeutic threshold probability by running a “natural disease history 
Markov model” over 10 years of a patient’s life (Figure 2-3). In this model, no testing is 
implemented. Instead, we assume that a hypothetical patient from the target population comes to 
the model with some known probability of having the disease. Two possible decisions are 
considered in the model: implementing prophylactic treatment or not, and we compare 
effectiveness (quality-adjusted years of life saved) associated with these decisions. We repeat 
this comparison given different levels of disease probability to see how effectiveness is 
influenced by disease probability. The therapeutic threshold is determined as such probability of 
having the disease, at which the quality adjusted years of life are the same both with and without 
the treatment.  
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Treat
No treat
No SLE
SLE
Death
No SLE
SLE
SLE
Death
Death  
Figure 2-3. Decision model for therapeutic threshold calculation 
 
In the base case, if the base parameter values (Table 2-2) are used in the natural history 
model, the therapeutic threshold equals 0.33, which corresponds to the expected value (EV) of 
effectiveness of 6.71 quality-adjusted years of life saved (Figure 2-4).   
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Figure 2-4. Effectiveness (quality-adjusted years of life) associated with treat and no-treat decisions under 
different levels of disease probability (left)2 and strategy graph showing the preferred decision (treat or no-
treat) under different levels of disease probability(right)3. 
  We next run a sensitivity analysis of the therapeutic threshold model to test the impact on 
the results of the assumptions made regarding key model parameters (Appendix ). We found that 
in particular, therapeutic threshold significantly depends on the utility associated with toxic 
                                                 
2 The two curves representing effectiveness of “treatment” and “no treatment” strategies, intersect when 
disease probability is 0.33. In this point, both strategies are equivalent in terms of their effectiveness. When the 
disease probability is <0.33, the “no treatment” strategy is superior to “treatment”. When the disease probability 
>0.33, the treatment strategy becomes more effective. 
3 The shaded areas represent the dominance of a particular strategy. If the disease probability <0.33, the 
“no treatment” strategy dominates; if the disease probability>0.33, the “treatment” strategy becomes dominating. 
 30
treatment side effects (uTox) (Figure 2-5). Therefore, to make the results of the analysis more 
comprehensive, the development of diagnostic strategies involving RBC and subsequent 
exploratory analysis of these strategies will be based not on a single base therapeutic threshold 
value, but on several ranges on therapeutic threshold corresponding to various intervals of uTox 
values. However, in the section below describing the development of RBC-involving testing 
strategies, a single arbitrary therapeutic threshold of 0.15 is used for simplicity (which provides 
more clear explanation than the base threshold of 0.33 as it is associated with more use of the 
RBC test). 
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Figure 2-5. Sensitivity analysis of utility associated with treatment side effects (uTox) on therapeutic 
threshold. 
2.2.9 DEVELOPMENT OF RBC-INVOLVING TESTING STRATEGIES: ELIMINATING REDUNDANT 
TESTS AND THE CHOICE OF THE LEAST COST TESTING STRATEGY 
We now identify various possible testing strategies that would involve the RBC test, and related 
post-test disease probabilities predicted from these strategies. We will make a treatment decision 
as follows: 
• If post-test disease probability > therapeutic threshold, then TREAT 
• If post-test disease probability < therapeutic threshold, then DON’T TREAT  
Out of 3 tests (ANA, DNA, RBC), 6 possible sequences can be constructed. For each of 
these sequences, we first assume that all 3 tests are done irregardless of results of previous tests 
results. Then redundant tests are eliminated as described below if they don’t influence treatment 
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decision under the given therapeutic threshold. This will give us 6 “abbreviated” 
testing/treatment strategies. 
  illustrates the elimination of redundant tests from the sequence ANA-DNA-RBC using 
an arbitrary value of the therapeutic threshold of 0.15. In case of positive ANA followed by 
positive DNA, running the RBC test does not affect the treatment decision, since the post-test 
disease probability is greater than the treatment threshold both when RBC is positive and 
negative. Therefore, patients will be treated both in case of positive and negative RBC test, so 
running the RBC test appears to be redundant. In case of positive ANA followed by negative 
DNA, and in case of negative ANA followed by negative DNA, running the RBC test results in 
the post-test disease probability less than the treatment threshold both in case of negative and 
positive RBC results. Hence patients will not be treated regardless of the RBC test result, and so 
this test can be eliminated again. However, running the RBC test after negative ANA and 
positive DNA does influence treatment decision, since in case of positive RBC, the posttest 
disease probability is higher than the therapeutic threshold, while in case of negative RBC, the 
posttest probability is lower than the therapeutic threshold. Therefore, the final test sequence will 
start with ANA followed by DNA, and then by RBC only in case of negative ANA, but positive 
DNA ( ).  
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Figure 2-6. Elimination of redundant tests in ANA-DNA-RBC sequence. 
 
Similarly, the redundant tests will be eliminated from other 5 possible testing sequences.  
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As a next step, we will choose the final strategy out of 6 “abbreviated” ones. At this point 
it is important to mention that the outcome (quality-adjusted years of life) does not depend on the 
order of the tests. Those patients will be treated who have positive ANA and DNA and those 
who have negative ANA but positive DNA and RBC. However, the order of the tests determines 
the expected cost of testing. Therefore, the finally chosen strategy should be the one that has the 
least expected cost.  
2.2.10 CHOICE OF THE LEAST COST TESTING STRATEGY 
Expected cost of six testing strategies is calculated from cost of tests (Table 2-2) and the full 
probability of running each of the tests. According to Table 2-3, under an arbitrary therapeutic 
threshold of 0.15, the DNA-ANA-RBC strategy would be preferred as the least cost one. 
Table 2-3. Expected cost of testing under various sequence of the tests (therapeutic threshold 0.15) 
Sequence Cost of testing, $ 
ANA-RBC-DNA 132.84 
RBC-ANA-DNA 153.99 
DNA-ANA-RBC 111.56 
DNA-RBC-ANA 113.00 
ANA-DNA-RBC 147.23 
RBC-DNA-ANA 166.10 
 
2.2.11 THERAPEUTIC THRESHOLDS INTERVALS AND RELATED RBC-INVOLVING STRATEGIES  
As was mentioned earlier, the therapeutic threshold is highly sensitive to the utility associated 
with negative treatment effects (uTox) (Figure 2-5). Different uTox values will be associated 
with different therapeutic thresholds. As the therapeutic threshold changes in sensitivity analysis, 
the treatment strategy changes discretely. For instance, as can be seen on  , in the sequence 
ANA-DNA-RBC, running RBC test becomes redundant after ANA-DNA+ if the treatment 
threshold to be between 0.239 and 0.373. In general for this sequence, if the therapeutic 
threshold is over 0.373 but below 0.852, treatment is applied only when all three tests are 
positive; if the therapeutic threshold is above 0.239, treatment is also applied when ANA and 
DNA are positive while RBC is negative; if the therapeutic threshold is over 0.127, treatment is 
also applied when ANA is negative, but DNA and RBC are positive; finally, if the therapeutic 
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threshold is over 0.032, treatment is applied when ANA is positive, DNA is negative and RBC is 
positive. 
We select four intervals of therapeutic thresholds. The borders of these intervals are 
selected so that when the therapeutic threshold crosses these borders, the treatment decision 
changes ( ). For instance, the when the therapeutic threshold is between 0.127 and 0.239, then 
treatment decisions are assigned as shown on in  . However, if the therapeutic threshold is just 
above 0.239, we are going to change our treatment decision not treating the patients with ANA 
negative, DNA positive, and RBC positive.  
For these four intervals of therapeutic threshold, we repeat the procedure of elimination 
of non-informative tests in six possible test sequences. From the six reduced testing strategies to 
be applied in each of these intervals, we then choose least cost strategies corresponding to the 
four intervals of therapeutic thresholds as described in previous sections. This will give us four 
least cost abbreviated strategies for each of the threshold intervals (Figure 2-8). 
The structure of the reduced testing strategies and their costs are represented in Table 
2-4. The expected costs of these strategies are plotted against 4 selected therapeutic threshold 
intervals in Figure 2-7. The reduced testing strategy resulting from the sequence ANA-RBC-
DNA is least cost for all therapeutic threshold intervals but 0.127 – 0.239. In the threshold 
interval 0.127 – 0.239, the reduced test strategy resulting from the DNA-ANA-RBC sequence is 
the least-cost. The least cost testing strategies for each of the threshold intervals are presented in 
Figure 2-8.  
Table 2-4. Test sequences, treatment strategies, and expected cost of reduced test strategies 
<0.127 Threshold 0.127-0.239 Threshold 0.239-0.373 Threshold 0.373-0.852 Threshold 
Sequence 
Strategy: treat if… Cost Strategy: treat if… Cost Strategy: treat if… Cost Strategy: treat if… Cost 
ANA-RBC-DNA 
ANA+RBC+DNA+ 
ANA+RBC+DNA- 
ANA+RBC-DNA+ 
ANA-RBC+DNA+ 
148.22 
ANA+RBC+DNA+ 
ANA+RBC-DNA+ 
ANA-RBC+DNA+ 
132.84 ANA+RBC+DNA+ ANA+RBC-DNA+ 95.59 ANA+RBC+DNA+ 82.81 
RBC-ANA-DNA 
RBC+ANA+DNA+ 
RBC+ANA+DNA- 
RBC+ANA-DNA+ 
RBC-ANA+DNA+ 
148.22 
RBC+ANA+DNA+ 
RBC+ANA-DNA+ 
RBC-ANA+DNA+ 
153.99 RBC+ANA+DNA+ RBC-ANA+DNA+ 95.59 RBC+ANA+DNA+ 83.24 
DNA-ANA-RBC 
DNA+ANA+RBC+ 
DNA+ANA+RBC- 
DNA+ANA-RBC+ 
DNA-ANA+RBC+ 
174.83 
DNA+ANA+RBC+ 
DNA+ANA+RBC- 
DNA+ANA-RBC+ 
111.56 DNA+ANA+RBC+ DNA+ANA+RBC- 110.58 DNA+ANA+RBC+ 113.07
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Table 2-4 (contd.)  
<0.127 Threshold 0.127-0.239 Threshold 0.239-0.373 Threshold 0.373-0.852 Threshold 
Sequence 
Strategy: treat if… Cost Strategy: treat if… Cost Strategy: treat if… Cost Strategy: treat if… Cost 
DNA-RBC-ANA 
DNA+RBC+ANA+ 
DNA+RBC+ANA- 
DNA+RBC-ANA+ 
DNA-RBC+ANA+ 
174.00 
DNA+RBC+ANA+ 
DNA+RBC+ANA- 
DNA+RBC-ANA+ 
113.00 DNA+RBC+ANA+ DNA+RBC-ANA+ 110.58 DNA+RBC+ANA+ 112.77
ANA-DNA-RBC 
ANA+DNA+RBC+ 
ANA+DNA+RBC- 
ANA+DNA-RBC+ 
ANA-DNA+RBC+ 
174.83 
ANA+DNA+RBC+ 
ANA+DNA+RBC- 
ANA-DNA+RBC+ 
147.23 ANA+DNA+RBC+ ANA+DNA+RBC- 95.59 ANA+DNA+RBC+ 98.08 
RBC-DNA-ANA 
RBC+DNA+ANA+ 
RBC+DNA+ANA- 
RBC+DNA-ANA+ 
RBC-DNA+ANA+ 
174.00 
RBC+DNA+ANA+ 
RBC+DNA+ANA- 
RBC-DNA+ANA+ 
166.10 RBC+DNA+ANA+ RBC-DNA+ANA+ 110.58 RBC+DNA+ANA+ 83.12 
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Figure 2-7. Expected cost after eliminating redundant tests for six test sequences and four intervals of 
therapeutic threshold. 
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Figure 2-8. Least-cost test strategies for four therapy threshold intervals for ANA-RBC-DNA test sequence. 
2.2.12 LEAST COST TRADITIONAL STRATEGY 
Our goal is to compare the RBC test performed together with traditional tests with the traditional 
tests alone. Therefore, we also select the least cost testing strategy for the combinations of the 
two traditional tests ANA and DNA for different values of therapeutic threshold. However, the 
treatment strategy is more robust for the combinations of two tests. According the posttest 
probabilities in Figure 2-9, for any therapeutic threshold between 0.084 and 0.626 the treatment 
is applied only when both ANA and DNA are positive. The least-cost strategy to detect patients 
with both ANA and DNA positive would require running DNA test after ANA (Table 2-5). 
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Figure 2-9. Elimination of redundant tests in ANA-DNA sequence 
 
Table 2-5. Test sequences, treatment strategies, and expected cost of reduced test strategies 
Sequence Strategy: treat if… Cost 
ANA-DNA ANA+DNA+ $95.6 
DNA-ANA DNA+ANA+ $110.6 
 
2.2.13 COST-EFFECTIVENESS ANALYSIS OF USING RBC TEST FOR SLE SCREENING  
2.2.13.1 Analysis 1 
The first analysis evaluates additional cost and effectiveness associated with simple adding of 
the RBC test to the traditional strategy (Figure 2-2).  
2.2.13.2 Analysis 2 
The ultimate goal of this analysis was to evaluate the incremental cost-effectiveness of using 
RBC test for SLE screening in conjunction with the traditional ANA and DNA tests. As follows 
from the previous sections, the introduction of RBC test to the traditional testing procedures in 
the least-cost way may result in both an increase and a decrease in the total expected cost of the 
testing depending on the therapeutic threshold (Figure 2-8). 
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In this section we run the cost-effectiveness analysis comparing the traditional SLE 
testing procedure based on ANA test followed by DNA test with the least cost testing strategy 
including RBC test. It is expected that using RBC test will result in an increase in quality 
adjusted years of life as a result of early disease detection and, on the other hand, avoidance of 
false positive diagnosis and unnecessary treatment. The additional test may also result in extra 
costs of SLE treatment as more patients may be tested positive. Finally, the cost of additional 
RBC test will contribute to the total cost increase. The proposed cost-effectiveness analysis will 
calculate the cost of the incremental quality adjusted year of life achieved with introduction of 
RBC test. 
Since the choice of optimal test strategy including RBC test depends on the therapeutic 
threshold and estimated negative effect of prophylactic treatment on false positives, we will run 
four cost-effectiveness analyses for the therapeutic threshold intervals corresponding to the least 
cost testing strategies shown in Figure 2-8.  
Each of the four cost-effectiveness analyses will use the utility of negative treatment 
effect consistent with the correspondent therapeutic threshold shown in Figure 2-5.  
Table 2-6 shows the uTox intervals corresponding to the therapeutic threshold intervals 
for each of the four strategies, and the values of uTox within these intervals used for the cost 
effectiveness analyses. 
 
Table 2-6. Therapeutic threshold intervals, uTox intervals and uTox values used for the four treatment 
strategies 
Strategy 
Therapeutic 
threshold 
intervals 
Corresponding 
uTox intervals
uTox value 
used for CEA
1 <0.127 0.88-1 0.890 
2 0.127-0.239 0.86-0.88 0.870 
3 0.239-0.373 0.825-0.86 0.843 
4 0.373-0.852 <0.825 0.800 
 
Cost-effectiveness analyses involve the same variables presented in Table 2-2.  
 38
2.3 RESULTS 
2.3.1 ANALYSIS 1 
As Table 2-7 shows, the traditional strategy dominates the RBC-involving one, since adding the 
RBC test is associated with greater costs (expected incremental cost is $552.3), and with lower 
effectiveness (expected 0.048 quality-adjusted years of life lost). 
Table 2-7. Results of the cost-effectiveness analysis of the strategy involving the RBC test with respect to 
traditional 
Strategy Cost QALYs ICER4 
ANA, DNA (traditional) 6369.5 7.379  
ANA, DNA, RBC 6921.8 7.331  
∆ 552.3 -0.048 -11,602.94 
 
2.3.2 ANALYSIS 2 
Results of the cost-effectiveness analyses of optimal strategies with respect to traditional are 
presented in Table 2-8. If therapeutic threshold is estimated as <0.127, then the optimal strategy 
involving RBC would be Strategy 1, where ANA is always followed by RBC test, and DNA is 
done in case of positive ANA, but negative RBC, and in case of negative ANA, but positive 
DNA (Figure 2-8). The incremental cost-effectiveness of this strategy with respect to the 
traditional strategy (ANA test followed by DNA in case of positive result on the former) is 
estimated as $48,165 per quality-adjusted year of life saved.  
 
                                                 
4 Incremental cost-effectiveness ratio 
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Table 2-8. Results of the cost-effectiveness analyses of optimal strategies with respect to traditional 
Therapeutic 
threshold interval Strategy 1 Cost Eff Incr C/E 
ANA, RBC, DNA $6,778.90 7.394  
ANA, DNA $6,369.50 7.386  <0.127 
 ∆ $409.40 0.0085 $48,164.71 
Strategy 2    
DNA, ANA, RBC $6,386.50 7.3831  
ANA, DNA $6,369.50 7.3828  
0.127-0.239 
 ∆ $17 0.0003 $56,666,67 
Strategy 4    
ANA, RBC, DNA $6,423.90 7.3765  
ANA, DNA $6,369.50 7.3734  
0.373-0.852 
∆ $54.40 0.0031 $17,548.39 
 
If therapeutic threshold is estimated as <0.127-0.239, then Strategy 2 would be optimal. 
In this strategy, DNA test is followed by ANA test in case of positive result of the former, and 
then RBC test follows in case of negative ANA (Figure 2-8). The incremental cost-effectiveness 
of this strategy compared to traditional is estimated $55,667 per quality-adjusted year of life 
saved.  
In case of even higher therapeutic threshold equivalent to 0.239-0.373, the optimal 
testing strategy coincides with traditional, and RBC test does not play any role (Figure 2-8).  
If therapeutic threshold reaches the values of 0.373-0.852, Strategy 4 becomes optimal. 
This strategy starts with ANA testing, followed by RBC in case of positive ANA result. If RBC 
test is positive, DNA test is done. The incremental cost-effectiveness of this strategy with respect 
to traditional is $17,548.  
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2.4 CONCLUSION 
• Under traditional strategies the same decision to treat patients with both positive DNA and 
ANA is made for the therapeutic threshold disease probability within a wide range of 
0.084 to 0.626 (see Figure 2-9). Introduction of RBC test to the traditional ANA and DNA 
tests complicates the treatment decision making. Now different treatment decisions must 
be made for therapeutic thresholds below 0.127, from 0.127 and 0.239, from 0.239 to 
0.373, and from 0.373 to 0.852 (Table 2-4). 
 
• The sensitivity analysis shows that the therapeutic threshold can significantly vary with 
the input parameters of the model, especially the negative effect of prophylactic treatment 
on false positives represented by the variable uTox (Figure 2-5). 
 
• If the therapeutic threshold is established for prophylactic treatment, introduction of RBC 
to the traditional strategies is the most cost-effective when the therapeutic threshold is 
very high. The incremental cost-effectiveness of RBC test to the traditional tests is 
$17,548 per adjusted years of life for the case of high therapeutic threshold in the range of 
0.373 to 0.852. The benefit from RBC test here comes from the reduction of false 
positives to which the treatment is applied. 
 
• At the lower levels of therapeutic threshold either the incremental cost-effectiveness of the 
RBC test is significantly higher ($48,165 and $56,667 for the threshold below 0.127 and 
between 0.127 and 0.239) or RBC test is redundant since it does not influence the 
treatment decision (for the threshold within 0.239 and 0.373).  
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2.5 SUMMARY 
In conclusion, our findings confirm that the choice of diagnostic strategy depends on the 
threshold disease probability. If it is low or high, the use of RBC test is warranted. Otherwise, 
the traditional strategy is the most reasonable one.  
If threshold disease probability is high, the strategy ANA-RBC-DNA is particularly 
powerful, since it yields a relatively low ICER ($17,548.39). However, since no agreement 
currently exists on what is a reasonable threshold for cost effectiveness of a new diagnostic 
strategy or a therapy, and since most of authors agree that it is currently far over $50,000, the 
strategies recommended under lower disease probability are also reasonable to use as they yield 
ICER $48,164.71 and $56,666.67. 
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3 Prevalence of Atherosclerosis and Associated Risk Factors in 
Women with Systemic Lupus Erythematosus 
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3.1 INTRODUCTION 
Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease with a wide 
spectrum of clinical presentations and mortality causes. Over the last decades, with improved 
management of the disease, patients die due to active lupus or an infection less frequently, but 
cardiovascular disease (CVD) has emerged as a significant threat to their health.  
The burden of CVD in SLE population is comprehensively described. An increased risk 
was particularly noted in young SLE patients [97-99]. Female lupus patients aged 35-44 are over 
50 times more likely to have myocardial infarction than are women of similar age without lupus 
[97]. Pathogenesis of vascular disease in lupus population is thought to be of atherosclerotic 
origin, and studying early subclinical manifestations of atherosclerosis in SLE patients is 
important for timely and successful interventions. Subclinical vascular disease in carotid arteries 
is evaluated using B-mode ultrasound, which measures the degree of focal plaque and intima-
media thickness (IMT) [100,101]. In the study of Roman et al., 37% SLE patients compared to 
15% controls had evidence of carotid plaque [98]. Calcification of coronary arteries and aorta 
measured by electron beam tomography (EBT) is another marker of subclinical vascular disease. 
It was shown that in SLE, the prevalence of coronary calcification and the mean coronary 
calcium scores were both significantly increased in lupus patients [99]. Aortic stiffness is a 
measure of functional rather than structural abnormalities of aorta. It is evaluated using pulse-
wave velocity (PWV), which measures the rate at which arterial pulse waves move along the 
vessel. Although all these subclinical markers were shown to be significant predictors of future 
cardiovascular events and mortality [102-104], few studies compared prevalence of subclinical 
vascular disease in different vascular beds (e.g., carotid and coronary) in women with SLE. 
While premature atherosclerosis in lupus patients is an accepted fact, the relationship 
between lupus and CVD is less clear. There are several potential mechanisms by which 
atherosclerosis may be accelerated in SLE. It is recognized that in addition to traditional 
cardiovascular risk factors, inflammatory and lupus-related factors are involved. However, the 
data on some of these factors are either contradictory or scarce. For instance, while duration of 
steroid exposure has been identified as a significant risk factor for future events [100], some 
studies found no relationship between steroid use and CVD [99,105]. Increased titers of 
antiphospholipid (aPL) antibodies are associated with an increased risk of vascular abnormalities 
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in some studies [106,107], while others have shown lower prevalence of aPL in patients with 
carotid plaque [98] or with coronary calcification [99]. The data on inflammatory markers are 
limited and controversial. Expression of endothelial cells sICAM-1 and E-selectin was elevated 
during exacerbation of SLE in one study [108], but not in the other [109]. Plasminogen activator 
inhibitor (PAI) was found to be increased in lupus patients with the history of thrombotic events 
[110]. However, the data on the relationship between inflammatory markers and atherosclerosis 
in SLE patients is mostly limited to the finding that increased CRP and low white cell count and 
albumin are associated with subclinical vascular disease [111]. In addition, overall, no agreement 
exists on which clinical manifestations or biomarkers are the best predictors of CVD in lupus 
patients. 
The present study was designed to extend our knowledge of subclinical vascular disease 
in patients with SLE by examining calcification of coronary arteries and aorta using EBT, and 
evaluating traditional, lupus-related and inflammatory risk factors associated with this 
phenomenon. The frequency and extent of focal carotid plaque and IMT were be evaluated using 
US, and the burden of atherosclerosis in the two vascular beds was be compared.  
 
3.2 PATIENTS AND METHODS 
3.2.1 STUDY COHORT  
3.2.1.1 SLE Patients 
The women recruited for this study are currently enrolled in the Pittsburgh Lupus Registry 
described previously [111]. All eligible women who were 18 years of age or older were invited 
to participate in the original cardiovascular study, regardless of their history of cardiovascular 
events. The first 300 women to respond were enrolled. Of these 300 patients, those 200 who are 
free of previous cardiovascular event (confirmed MI or stroke, or a physician diagnosis of angina 
or transient ischemic attach (TIA)), are being recruited for evaluation of calcification of the 
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coronary arteries and aorta using EBT5. Criteria for defining a myocardial infarction, stroke, 
angina and transient ischemic attack were taken from the Cardiovascular Health Study [112]. 
The University of Pittsburgh’s Institutional Review Board approved this study, and all women 
provided written informed consent prior to participation. Each participant provided an 
authorization for release of medical information so that pertinent hospital and outpatient records 
could be reviewed to confirm aforementioned events. The analyses presented in this report 
include those CVD event-free 137 women who have all the data completed by far.  
3.2.1.2 Controls 
The control group recruited for this study consisted of healthy women free of previous 
cardiovascular event and matched to cases by age (5-year interval), race and geographical 
location. For the present analysis, we used the data on 106 control subjects.  
3.2.2 VARIABLE MEASUREMENT 
Participation in the study consisted of an interview, physical examination, laboratory tests, 
carotid ultrasound scan and EBT, all of which took place on the same day. Several groups of risk 
factors were evaluated.  
3.2.2.1 Traditional Cardiovascular Risk Factors.  
The questionnaires were used to obtain the information on age, race, education level, household 
income, smoking habits (current use and total pack-years), family history of cardiovascular 
disease (MI, stroke, or sudden death in a first-degree relative before the age of 60 years), 
menopausal status (follicle-stimulating hormone levels were obtained when menopausal status 
was uncertain), use of estrogen replacement therapy and diabetes (use of oral hypoglycemic 
agents or insulin). Body mass index (calculated from height and weight) and waist-to-hip ratio 
were obtained using a standard protocol. Current blood pressure status was determined using an 
average of 2 consecutive sitting blood pressure readings. Levels of total cholesterol, low-density 
lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride, glucose, 
                                                 
5HEARTS Study: Heart Effects of Atherosclerosis and Risks of Thrombosis in SLE. Principal Investigator: 
S. Manzi, MD, MPH; Research Support: NIH RO1 AR46588-01 
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insulin and homocysteine levels were measured in fasting blood samples using standardized 
laboratory tests. Hypertension was defined as an average systolic blood pressure ≥140 mmHg or 
an average diastolic blood pressure ≥90 mmHg or the use of antihypertensive agents. Diabetes 
was defined according to the American Diabetes Association criteria. Hyperlipidemia as defined 
either by diagnosis, or by the use of antidiabetic drugs. A blood clot was confirmed by medical 
records upon the report of a clot made by a patient.  
3.2.2.2 SLE-Related Disease Factors.  
SLE-disease activity was measured using the Systemic Lupus Activity Measure (SLAM) [113] 
and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Cumulative organ 
damage was measured by the Systemic Lupus International Collaborating Clinics (SLICC) 
damage index [114] and a modified version of SLICC that excluded several of the cardiovascular 
variables, such as angina, MI, and coronary artery bypass surgery. In order to complete these 
indices, we have obtained a routine cell sedimentation rate (ESR), antibodies to native DNA 
(double-stranded DNA (dsDNA) determined by immunoflurescence with Crithidia lucillae 
kinetoplast assay), and C3 and C4 complement levels. Information on corticosteroid therapy 
(current use, maximum dose, cumulative dose, and duration of use), hydroxychloroquine and 
immunosuppressant use was collected. Renal disease was defined using the SLICC renal 
variable, which requires the presence of nephrotic-range protenuria (≥3.5 grams/24 hours) or 
renal insufficiency (glomerular filtration rate < 50%). Other laboratory studies included a lupus 
anticoagulant test [partial thromboplastin time (APTT, APTT with mix) or dilute Russell’s viper 
venom time (dRVVT)], as well as tests for anticardiolipin antibodies (IgG>15 GPL units, IgM 
>10 MPL units; Incstar, Stillwater, MN).  
3.2.2.3 Immune and Inflammatory Markers.  
Serum albumin (dye binding assay), C-reactive protein (ultrasensitive colometric ELISA), 
fibrinogen (modified clot-rate assay), soluble intercellular adhesion molecule-1 (sICAM-1), E-
selectin, soluble CD40L (ELISA), and plasminogen activator inhibitor-1 (PAI-1) levels were 
measured.  
Each laboratory test was done in the same lab for all the study participants. 
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3.2.3 VASCULAR DISEASE MEASUREMENTS 
EBT was used to provide 2 disease measures: coronary calcification and aortic calcification. The 
EBT scanning protocol was done in the Preventive Cardiology Center in the Division of 
Cardiology at the University of Pittsburgh Medical Center directed by Dr. D.Edmundowicz. The 
scanning was done using an Imatron C-150 Ultrafsat CT Scanner (Imatron, South San Francisco, 
CA) and standard protocol. The calcium scoring method was the same for coronary and aortic 
images. The total calcium score was calculated with a densitometric program available on the 
Imatron C-150 scanner using the Agatston method. We tested within-reader variability and 
between-reader reliability on an ongoing basis.  
Carotid ultrasound was performed at the University of Pittsburgh Epidemiology 
Ultrasound Research Laboratory under the direction of Dr. K. Sutton-Tyrrell as previously 
described [100]. Briefly, a Toshiba SSA-270A scanner (Tustin, CA) equipped with a 5-MHz 
linear array imaging probe was used to image the right and left common artery, carotid bulb, and 
the first 1.5 cm of the internal and external carotid arteries. Plaque was defined as a distinct focal 
area protruding into the vessel lumen, with at least 50% greater thickness than that found in 
surrounding areas. For each segment scanned, the degree of plaque was graded as follows: 0 = 
no observable plaque; 1 = one small plaque (less than 30% of the vessel diameter); grade 2 = one 
medium plaque (between 30% and 50% of the vessel diameter) or multiple small plaques; grade 
3 = one large plaque (greater than 50% of the vessel diameter) or multiple plaques with at least 
one medium plaque. The grades were summed across the right and the left carotid arteries to 
create the combined plaque index (possible range 0-30), the overall measure of the extent of 
focal plaque.  
Intima-media thickness (IMT) was measured across 1-cm segments of both the right and 
left sides of the near and far walls of the distal common carotid artery and the far wall of the 
carotid bulb and the internal carotid artery. Values from each location were averaged to produce 
an overall measure of IMT. The reproducibility of carotid scanning has previously been 
documented [100].  
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3.2.4 STATISTICAL ANALYSIS 
The distributions of aortic and coronary calcification scores, the main outcomes of interest, were 
heavily skewed. The calcium scores were dichotomized by the cutpoint of 0 score 
(absence/presence of calcium), or divided by natural cutpoints for the coronary arteries (0, 10 
and 100 calcium score) and aorta (0 and 300 calcium score). The descriptive analyses were 
summarized as means, medians and ranges for continuous variables and as percentages for 
categorical variables. All risk factors were screened univariately, and those variables 
significantly associated with the presence of coronary and aortic calcium at the α=0.20 level of 
significance, were subsequently assessed in stepwise multivariate analyses. Statistical tests used 
for the univariate analyses included t-test for normally distributed continuous data, Wilcoxon 
rank sum test when the assumptions of the t-test were not met, and chi-square tests or Fisher’s 
exact test for categorical data. Continuous risk factors were either used in their original forms or 
split into categories based on means, quartiles, or natural cut-off points. SAS-pc (SAS institute, 
Cary, NC) was used to perform all statistical procedures. 
Stepwise binary logistic regression was utilized to build models evaluating independent 
risk factors related to the presence of coronary or aortic calcium, in the total study cohort and in 
the subsets of pre- and postmenopausal patients. Ordinal logistic regression (cumulative logit) 
was used to identify risk factors associated with severity of calcification. Model assumptions 
(Hosmer and Lemeshow goodness-of-fit and score test for proportional odds) were used to assess 
model fit [115]. All the multivariate models were controlled by age, a known determinant of 
EBT-detected vascular disease [116,117]. 
Other outcomes included the presence (yes/no) and severity (plaque index 0, 1, 2, or ≥3) 
of carotid plaque and IMT. On the subset of patients (N=70) whose carotid ultrasound and EBT 
were done within one year, we evaluated the association between the two measures of 
atherosclerosis. 
3.2.5 STATISTICAL POWER 
Based on our power computations, we designed a study that recruited 100 cases. Power 
calculations for the multiple logistic regression models incorporated the multiple correlation 
coefficient 2ρ  relating the specific covariate of interest to the remaining covariates, P0 - the 
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probability of events at mean value of all covariates (using 0 value for binary covariates), and the 
OR of disease corresponding to a one standard deviation change from the mean value of the 
specific covariate6, given the mean values of the remaining covariates [118]. The calculations are 
performed using P0 for the coronary calcification is equal to 0.31 [119], 2-tailed test, 
alpha=0.05.   
With 100 cases, and assuming P0 of 0.31, we had 80% power to detect an OR for a main 
effect (e.g., cardiovascular risk factor of ESR) of 1.97 at alpha=0.05, assuming the multiple 
correlation coefficient relating the main effect of interest and other covariates in the model is 0.2. 
Even if the multiple correlation coefficient was as high as 0.4, we still had 80% power to detect 
an OR of 2.19 for one standard deviation change in ESR. PASS software was used to perform 
power estimation (NCSS Statistical Software, Kaysville, UT). 
 
3.3 RESULTS 
3.3.1 PATIENT POPULATION 
The 137 women with SLE were predominantly Caucasian (86%), and had a mean age of 
49.5±10.0 years, and disease duration of 16.3±7.2 years. Compared with all women in the 
Pittsburgh Lupus Registry (n=983), the study participants were slightly younger (49.9±10.18 
years versus 51.8±14.7 years7 [111]), had somewhat longer disease duration (16.7±7.60 years 
versus 14.8±7.1 years [111]) and higher proportion of Caucasian (86% versus 84.4% [111]). 56% 
of the study participants were postmenopausal. The presence of coronary calcium was detected 
in 49.6% of patients and aortic calcium was found in 80.3%.  
3.3.2 COMPARISON OF CORONARY AND AORTIC CALCIFICATION AMONG CASES AND 
CONTROLS 
Coronary and aortic calcification data were available for 106 control subjects. They were not 
significantly different from cases in terms of age (controls: 50.94 ±8.02 years, cases: 49.5±10.0 
                                                 
6 Therefore, OR for a 1 unit change should be transformed as OR*std 
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years, p=0.25). However, there were more Caucasians among controls than among cases, (93.4% 
vs. 86.4%, p=0.078) and fewer postmenopausal subjects (45.3% vs. 57.1%, p=0.065). 
 
The presence of coronary calcium was detected in 50.9% of control subjects, which was 
not significantly different from cases (49.6%, p=0.88). However, among controls, there were 
significantly fewer subjects with coronary calcium score≥ 10 than among cases (15.1% vs. 
27.9%, p=0.017). Aortic calcium was significantly less prevalent among controls than among 
cases (67.9% vs. 80.3%, p=0.02). 
3.3.3 RISK FACTORS ASSOCIATED WITH CORONARY AND AORTIC CALCIFICATION IN SLE 
PATIENTS 
3.3.3.1 Univariate Analysis 
Univariate analysis compares traditional cardiovascular, SLE-specific and inflammatory 
variables between SLE subjects with and those without calcium in coronary artery and aorta 
(calcium score cutpoint of 0). The study participants with either coronary or aortic calcium 
tended to be older compared to those without calcification (p<0.01). The group with coronary 
calcification was characterized by lower percentage of Caucasians (80.9% vs. 91.3%, p<0.1) and 
higher percentage of postmenopausal patients (69.1% vs. 43.5%, p<0.01) compared to the group 
without coronary calcium. Patients with either type of calcification had higher systolic, diastolic 
and pulse pressure, higher insulin levels, cumulative organ damage assessed by SLICC, and 
higher levels of inflammatory markers, such as CRP, PAI-1, sICAM-1 (both for subjects with 
coronary and aortic calcification), ESR, fibrinogen, E-selectin (for subjects with coronary 
calcification) (Table 3-1).  
                                                                                                                                                             
7 The numbers for the Pittsburgh Lupus Registry are derived from literature; therefore, no p value is 
calculated  
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Table 3-1. Comparison of traditional cardiovascular, SLE-specific and inflammatory risk factors in the 137 
female SLE patients with versus without coronary calcification (Ca), and with versus without aortic 
calcification* 
Variable No coronary Ca (N=69) 
Coronary Ca 
(N=68) 
No aortic Ca 
(N=27) 
Aortic Ca 
(N=110) 
Overall 
(N=137) 
Age, years 45.5±8.3 53.6±10.0† 42.8±8.1 51.2±9.7† 49.5±10.0 
Race, % white 91.3 80.9§ 81.5 87.3 86.1 
SLE duration, years 16.2±7.6 16.4±6.8 14.4±6.8 16.7±7.3§ 16.3±7.2 
Postmenopausal, % 43.5 69.1† 44.4 59.1 56.2 
Body mass index, kg/m2 26.7±15.0 31.4±6.1† 27.9±23.0 29.3±6.6† 29.0±11.7 
Waist hip ratio 0.8±0.1 0.9±0.1† 0.8±0.1 0.9±0.1 0.8±0.1 
Systolic BP, mm Hg 110.9±13.4 129.7±19.1† 106.1±11.7 123.7±18.7† 120.2±18.9 
Diastolic BP, mm Hg 74.0±9.0 80.3±10.8† 71.4±10.2 78.5±10.0† 77.1±10.4 
Pulse pressure, mm Hg 36.9±8.8 49.4±13.8† 34.7±6.0 45.2±13.5† 43.1±13.1 
Hypertensive, % 36.2 70.6† 29.6 59.1† 53.3 
Total cholesterol, mg/dl 187.6±41.2 191.2±38.5 176.2±35.1 192.6±40.3§ 189.4±39.8 
Median glucose, mg/dl 87.0 89.0§ 86.0 89.0 89.0 
Median triglycerides, mg/dl 108.0 126.5‡ 109.0 118.0 116.0 
Insulin, µU/ml 12.0±6.8 18.6±11.2† 11.7±9.3 16.1±9.7† 15.2±9.8 
SLE cumulative organ damage 1.0±1.2 1.7±1.9‡ 0.9±1.3 1.4±1.6§ 1.3±1.6 
C3, mg/dl 93.0±23.0 107.2±31.7† 94.0±21.3 101.5±29.9 100.0±28.5 
C4, mg/dl 18.0±6.4 21.6±8.0† 18.8±6.3 20.1±7.6 19.8±7.4 
WBC count, 103/mm3 4.9±1.8 5.9±2.0† 5.2±2.2 5.5±1.9 5.4±1.9 
Median CRP, mg/nl 1.5 4.1† 1.9 2.6§ 2.6 
Median ESR, mm/h 9.0 13.0§ 12.0 10.0 10.0 
Median PAI-1, ng/ml 11.9 23.4† 11.8 16.6§ 14.6 
Median fibrinogen, mg/dl 306.0 356.0† 302.0 343.5 340.0 
E-selectin, ng/ml 42.0±18.8 51.9±21.9† 46.8±24.2 50.0±20.5 49.4±21.2 
Median sICAM-1, ng/ml 255.0 285.7§ 243.2 269.4‡ 264.9 
*Except where otherwise indicated, values are the mean ± SD. BP = blood pressure. 
† P≤ 0.01 versus those with no calcification. 
‡ P≤ 0.05 versus those with no calcification. 
§ P≤ 0.10 versus those with no calcification. 
# Women were considered to have hypertension if they were taking antihypertensive medication or their sitting 
systolic blood pressure was >140 mm Hg or their diastolic blood pressure was >90 mm Hg. 
 
 
3.3.3.2 Multivariate Analysis 
In the binary logistic regression, risk factors independently associated with the presence of 
coronary calcification included older age (OR=1.11, p<0.01), race (being Caucasian appeared to 
have protective effect, OR=0.14, p=0.02), elevated systolic blood pressure (OR=1.09, p<0.01), 
WBC count (OR=1.85, p<0.01), ESR (OR=1.04, p=0.05) and PAI-1 (OR=3.09, p<0.01). The 
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independent determinants of severity of coronary calcification were older age (OR=1.07, 
p<0.01), pack-years of smoking (OR=1.03, p=0.09), and, similar to the regression on the 
presence of coronary calcium, elevated systolic blood pressure (OR=1.04, p<0.01), WBC count 
(OR=1.27, p=0.02), ESR (OR=1.03, p=0.03) and PAI-1 (OR=1.93, p<0.01) (Table 3-2).   
Independent determinants of the presence of aortic calcium in the multivariate analysis 
were older age (OR=1.07, p=0.03), elevated systolic blood pressure (OR=1.07, p<0.01), and 
PAI-1 (OR=1.47, p=0.1). Factors independently associated with severity of aortic calcification 
included older age (OR=1.12, p<0.01), pack-years of smoking (OR=1.05, p=0.03), higher SLE-
related cumulative organ damage as measured by SLICC damage index (OR=1.31, p=0.03), 
decreased platelets (OR=0.99, p=0.04) and sICAM-1 (OR=1.01, p=0.01) (Table 3-3). 
Table 3-2. Logistic regression analysis of variables associated with the presence and severity of coronary 
calcification in women with SLE (N=137)*. 
 Presence of coronary calcium  Severity of coronary calcification 
Explanatory variable Odds ratio 90% CI P  
Odds 
ratio 90% CI P 
Age, years 1.11 1.05-1.16 <0.01  1.07 1.03-1.10 <0.01 
Race** 0.14 0.04-0.60 0.02  - - - 
Pack-years of smoking - - -  1.03 1.01-1.06 0.09 
Systolic blood pressure, mm Hg 1.09 1.05-1.13 <0.01  1.04 1.02-1.06 <0.01 
WBC, 103/mm3 ng/ml 1.85 1.39-2.47 <0.01  1.27 1.08-1.49 0.02 
ESR, mm/h 1.04 1.01-1.07 0.05  1.03 1.01-1.06 0.03 
PAI-1, ng/ml 3.09 1.94-4.91 <0.01  1.93 1.46-2.57 <0.01 
*Presence of coronary calcium: calcification score>0; severity of coronary calcification: 0 – calcification score=0 
(N=69); 1 – calcification score 1-10 (N=27); 2 – calcification score 10-100 (N=22); 3 – calcification score >100 
(N=19).  
**0 – non-Caucasian, 1 – Caucasian 
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Table 3-3. Logistic regression analysis of variables associated with the presence and severity of aortic 
calcification in women with SLE (N=137)*. 
 Presence of aortic calcium  Severity of aortic calcification 
Explanatory variable Odds ratio 90% CI P  Odds ratio 90% CI P 
Age, years 1.07 1.02-1.12 0.03  1.12 1.08-1.16 <0.01 
Pack-years of smoking - - -  1.05 1.01-1.09 0.03 
Systolic blood pressure, mm Hg 1.07 1.03-1.10 <0.01  - - - 
SLE cumulative organ damage - - -  1.31 1.07-1.61 0.03 
Platelets, 103/mm3 - - -  0.99 0.99-0.999 0.04 
sICAM, ng/ml - - -  1.01 1.00-1.01 0.01 
PAI-1, ng/ml 1.47 1.00-2.17 0.10  - - - 
*Presence of aortic calcium: calcification score>0; severity of aortic calcification: 0 – calcification score=0 (N=27); 
1 – calcification score 1-300 (N=74); 2 – calcification score >300 (N=36).  
 
3.3.4 RISK FACTORS FOR CORONARY AND AORTIC CALCIFICATION BY MENOPAUSAL STATUS 
Comparing risk factors associated with calcification in pre- and postmenopausal SLE patients is 
a promising area. However, considering the sample size, this report is limited to the univariate 
rather than multivariate analysis. In the group of premenopausal patients (N=60), those with 
calcification tended to be have higher body mass index and waist-to-hip ratio compared to 
women of the same group without calcification. Premenopausal women with coronary calcium 
were likely to be hypertensive, to have increased systolic and diastolic blood pressure, pulse 
pressure, elevated triglycerides and insulin levels. Their complement C3 and WBC count tended 
to be significantly increased, as well as all the inflammatory markers measured. In the group of 
postmenopausal women, those with coronary calcification were older, tended to be heavier 
smokers and to have higher body mass index than patients of the same group without 
calcification. Postmenopausal patients with coronary calcium also were likely to be hypertensive 
and had increased systolic blood pressure, pulse pressure and insulin. They tended to have higher 
SLE-related cumulative organ damage as measured by SLICC, elevated complement C3 and C4, 
and WBC count. Among all inflammatory markers measured, only CRP, PAI-1 and E-selectin 
were significantly associated with coronary calcification in postmenopausal women (Table 3-4).  
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 Table 3-4. Characteristics of pre- ad postmenopausal SLE patients, according to the presence or absence of 
calcification in the coronary artery* 
Premenopausal (N=60)  Postmenopausal (N=77) 
Variable No Calcification 
(N=39) 
 Calcification 
(N=21) 
 No Calcification 
(N=30) 
 Calcification 
(N=47) 
Age, years 41.7±6.0  44.1±6.8  50.3±8.4  57.9±8.1† 
Pack-years of smoking 1.7±5.2  1.8±6.8  2.6±5.1  11.0±18.0§ 
Body mass index, kg/m2 27.7±19.5  33.5±5.8†  25.4±4.8  30.5±6.1† 
Waist hip ratio 0.8±0.1  0.9±0.1§  0.8±0.1  0.9±0.1 
Systolic BP, mm Hg 107.7±11.3  124.1±16.5†  115.2±14.8  132.2±19.8† 
Diastolic BP, mm Hg 71.6±8.3  79.5±10.3†  77.1±9.1  80.7±11.1 
Pulse pressure, mm Hg 36.0±7.3  44.6±10.2†  38.1±10.4  51.5±14.7† 
Hypertensive, %# 25.6  52.4‡  50.0  78.7† 
Median triglycerides, mg/dl 101.0  119.0‡  121.0  127.0 
Insulin, µU/ml 11.9±8.1  20.8±11.1†  12.1±4.8  17.6±11.2‡ 
SLE cumulative organ 
damage 0.7±1.0 
 1.0±1.2  1.2±1.3  2.0±2.0§ 
C3, mg/dl 88.4±23.6  101.6±35.6‡  98.9±21.1  109.7±29.9‡ 
C4, mg/dl 17.6±6.1  19.3±7.5  18.6±6.7  22.6±8.0‡ 
WBC count, 103/mm3 5.0±2.0  5.9±2.0§  4.8±1.3  5.9±2.0‡ 
Leukopenic, % 33.3  14.3  30.0  8.5‡ 
Median ESR, mm/h 6.0  15.5§  12.0  4.0 
Median CRP, mg/nl 1.0  5.6†  2.6  11.0§ 
Median PAI-1, ng/ml 12.6  24.5†  11.8  21.4† 
Median fibrinogen, mg/dl 302.0  357.0†  340.5  346.0 
E-selectin, ng/ml 43.4±20.6  53.5±18.2‡  45.8±16.6  55.0±24.2§ 
Median sICAM-1, ng/ml 241.1  277.7‡  264.1  286.9 
*Except where otherwise indicated, values are the mean ± SD. BP = blood pressure. 
† P≤ 0.01 versus those with no calcification. 
‡ P≤ 0.05 versus those with no calcification. 
§ P≤ 0.10 versus those with no calcification. 
# Women were considered to have hypertension if they were taking antihypertensive medication or their sitting 
systolic blood pressure was >140 mm Hg or their diastolic blood pressure was >90 mm Hg. 
 
Table 3-5 represents characteristics of pre- and postmenopausal patients according to the 
presence or absence of calcium in aorta. Among premenopausal patients, variables significantly 
associated with the presence of aortic calcium were older age, higher body mass index, elevated 
systolic and diastolic blood pressure, pulse pressure, and insulin. No significant relationship was 
found between aortic calcium and lupus-specific or inflammatory markers in this group of 
patients. Risk factors significantly associated with aortic calcification among postmenopausal 
patients were older age, heavier smoking, higher body mass index, systolic blood pressure, pulse 
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pressure, median glucose, insulin, hypertension, and elevated WBC count. Among inflammatory 
markers, only CRP, PAI-1 and sICAM-1 were increased in postmenopausal women with aortic 
calcium compared to those without calcification (Table 3-5). 
Table 3-5. Characteristics of pre- ad postmenopausal SLE patients, according to the presence or absence of 
calcification in aorta* 
Premenopausal (N=60)  Postmenopausal (N=77) 
Variable No Calcification 
(N=15) 
 Calcification 
(N=45) 
 No Calcification 
(N=12)  
Calcification 
(N=65) 
Age, years 39.0±6.5  43.7±5.8‡  47.5±7.6  56.3±8.5† 
Pack-years of smoking 0.8±1.9  2.1±6.5  0.7±1.7  17.2±7.7§ 
Body mass index, kg/m2 31.2±30.8  29.3±7.3‡  23.8±3.5  29.4±6.1† 
Systolic BP, mm Hg 103.1±9.5  116.8±15.6†  109.8±13.6  128.4±19.4† 
Diastolic BP, mm Hg 68.3±8.4  76.4±9.4†  75.3±11.3  80.0±10.2 
Pulse pressure, mm Hg 34.8±4.2  40.4±10.1‡  34.7±7.9  48.4±14.7† 
Median glucose, mg/dl 89.0  86.0  85.0  90.0§ 
Insulin, µU/ml 12.5±11.9  15.7±9.4‡  10.8±4.7  16.3±10.0‡ 
Hypertensive, %# 20.0  40.0  41.7  72.3‡ 
WBC count, 103/mm3 5.7±2.6  5.2±1.9  4.6±1.5  5.7±1.9§ 
Leukopenic, % 26.7  26.7  41.7  12.3‡ 
Median CRP, mg/nl 1.9  1.6  2.2  3.2‡ 
Median PAI-1, ng/ml 11.0  14.4  12.6  17.2§ 
Median sICAM-1, ng/ml 225.6  257.7  246.3  287.5‡ 
*Except where otherwise indicated, values are the mean ± SD. BP = blood pressure. 
† P≤ 0.01 versus those with no calcification. 
‡ P≤ 0.05 versus those with no calcification. 
§ P≤ 0.10 versus those with no calcification. 
# Women were considered to have hypertension if they were taking antihypertensive medication or their sitting 
systolic blood pressure was >140 mm Hg or their diastolic blood pressure was >90 mm Hg. 
 
3.3.5 ASSOCIATION BETWEEN CORONARY AND AORTIC CALCIFICATION (EBT) AND 
CAROTID PLAQUE (DOPPLER ULTRASOUND) IN SLE PATIENTS 
The relationship between calcification of the coronary arteries and aorta measured by EBT and 
carotid atherosclerosis assessed by the ultrasound was evaluated on the subset of 70 study 
participants who had carotid ultrasound scan and EBT done within one year. According to the 
carotid ultrasound scans, 18 of these 70 women (25.7%) had at least 1 focal plaque (plaque index 
>0). The overall mean IMT for far and near walls of the common carotid artery (CCA), carotid 
bulb and internal carotid artery (ICA) was 0.64±0.09 for these 70 patients, and mean IMT for 
bulb and ICA only 0.63±0.11. 
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As shown on Figure 3-1, there was significant association between presence of at least 1 
focal carotid plaque (plaque index >0) and presence of calcium in the coronary artery (p=0.09). 
The presence of carotid plaque was also significantly related to the aortic calcification score 
above the median (>30.5) (p=0.02); however, no association was found between carotid plaque 
and aortic calcium score >0. 
43.1
72.6
41.2
66.7
88.9
72.2
0
20
40
60
80
100
Coronary calcium >0
(p=0.086)
Aortic calcium >0
(p=0.205)
Aortic calcium > 30.5
(p=0.023)
Fr
eq
ue
nc
y,
 %
No carotid plaque Carotid plaque   
Figure 3-1. Association between the presence of coronary and aortic calcification (EBT) and carotid plaque 
(Doppler US) 
IMT scores (carotid US) were averaged for far and near walls of the common carotid 
artery, carotid bulb and ICA (estimate 1), and separately for the bulb and ICA (estimate 2). Both 
IMT estimates were found to be significantly associated with the presence of calcium both in 
coronary artery and aorta as measured by EBT (Figure 3-2).  
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Figure 3-2. Association between carotid IMT (Doppler US) and presence of coronary and aortic calcium 
(EBT) 
 57
  
3.4 DISCUSSION 
The study represents new data on the presence, severity and determinants of coronary and aortic 
atherosclerosis in women with SLE using EBT; this is the first study that compares the 
prevalence of EBT-detected atherosclerotic burden among SLE patients and age- and race-
matched controls. We found coronary calcium in 49.6% of patients. Asanuma et al. recently 
reported the 31% rate of coronary calcium detected by EBT in their 65 lupus patients [99], which 
is lower than in our study. This difference can be related to older mean age of our study cohort 
(49.5±10.0 years versus 40.3±11.6) and longer disease duration (16.3±7.2 years vs. 9.9±8.7 
years). Using a myocardial perfusion technique, Bruce et al. found abnormalities of coronary 
artery in 35% of SLE patients [105], which is also lower than our EBT-detected estimate of 
coronary atherosclerosis. It should be noted that perfusion techniques rely on flow-limiting 
stenosis and may underestimate the prevalence of coronary atherosclerosis. 
We found no significant difference among cases and controls in terms of the presence of 
the coronary calcium. However, among controls, there were fewer subjects with clinically 
significant coronary calcium score≥ 10 than among cases (15.1% vs. 27.9%, p=0.017). 
Aortic calcium was also significantly less prevalent among controls than among cases 
(67.9% vs. 80.3%, p=0.02). Our estimates are consistent with previous findings that SLE 
subjects are at higher risk for coronary and aortic atherosclerosis than non-lupus population 
[120,121]. 
In our study, the prevalence of calcium in the aorta was significantly higher than in the 
coronary artery (80.3% vs. 49.6%). Although no data on EBT-detected calcium in aorta was 
previously reported for SLE population, higher prevalence of aortic calcification compared to 
coronary is consistent with previous observations in non-SLE middle-aged women [120] and 
with autopsy studies which reported a smaller percentage of the coronary artery surface involved 
with atherosclerotic lesions than either the thoracic or abdominal aorta surface [122]. This can be 
explained by earlier onset of aortic calcification compared to coronary. Younger age of patients 
with aortic calcification (51.9±9.8 years of age) compared to patients with coronary calcification 
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(54.2±10.2 years of age) in our study is consistent with this tendency. It was noted that aorta is 
not protected by estrogen as much as the coronary artery, and in this sense, represents a longer 
exposure to the adverse risk factors [123,124]. It can therefore be suggested that in young 
women with SLE, the measurement of aortic rather than coronary calcium may provide earlier 
evaluation of underlying atherosclerosis.  
Risk factors associated with development of atherosclerosis in SLE cohort are traditional 
cardiovascular, lupus-related and inflammatory. In our study, traditional cardiovascular risk 
factors independently associated with the presence and severity of atherosclerosis in the 
coronary artery and aorta were older age, non-Caucasian race, smoking history and elevated 
systolic blood pressure. Most of these results are consistent with findings of other authors. Age is 
a known risk factor for atherosclerosis of coronary and carotid arteries and aorta in SLE 
[100,111,125]. Smoking was found to be significantly associated with coronary calcification in 
SLE patients [125] and with focal carotid plaque among non-lupus women [101]. Elevated 
systolic blood pressure was identified as a risk factor associated with atherosclerosis in previous 
SLE studies [100,111] and in the study conducted on premenopausal non-SLE women [101]. 
However, observing higher prevalence of atherosclerosis among non-Caucasians than in whites 
is less common. In the study of Newman et al. on non-SLE population, older black subjects (80+ 
year old) had lower coronary artery calcium (CAC) score than did white, although these 
differences were less pronounced in younger cohorts (75-79 year old) [126]. 
Among SLE-specific risk factors, elevated WBC count was noted to be associated with 
the presence and severity of coronary calcification. Cumulative organ damage (SLICC index), as 
well as decreased platelet count, were found to be significantly associated with severity of aortic, 
but not coronary calcification. This confirms that, as was noted earlier, aorta is protected by 
estrogen less than the coronary artery, and thus is more exposed to adverse risk factors. Overall, 
our findings are consistent with results of other studies. Patients with more cumulative organ 
damage were found to be more likely to have a stiffer aorta [127]. Damage-index score was 
found to be an independent determinant of carotid plaque detected by ultrasonography and B-
mode ultrasound [98,100]. Decreased platelet count is a typical indicator of systemic lupus. 
Elevated WBC count suggests the ongoing inflammatory process and thought to be associated 
with atherogenesis. Although the data on association of WBC count and subclinical vascular 
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disease in SLE patients is scarce, elevated WBC count was shown to be a significant predictor of 
cerebral infarction incidence in the general population [128].  
The multivariate analyses of our study showed no significant relationship between 
calcification and lupus activity indices, such as SLAM and SLEDAI, or typical laboratory 
assays, such as complement C3 and C4 and dsDNA. This can be related to the fact the systemic 
lupus is a chronic disease characterized by flares and remissions, and measures of disease 
activity and laboratory tests fluctuate respectively. As a result, their cross-sectional measures 
cannot reliably reflect a chronic process of atherosclerosis in SLE. In contrast, SLICC index 
reflects irreversible, cumulative effect of SLE, and its independent association with 
atherosclerosis is particularly informative and thus important.   
Inflammatory markers. We found an independent association of increased ESR and PAI-
1 with presence and severity of coronary calcification, and association of PAI-1 and sICAM-1 
with the presence and severity of aortic calcification, respectively. This is consistent with 
findings reported by other researchers. ESR was found significantly increased in SLE patients 
with a history of CVD compared to SLE controls without such a history and to non-SLE controls 
[129]. Elevated PAI-1 levels worsen the prognosis of myocardial infarction and are associated 
with an increased risk of cardiovascular disease in general population [130]. Increased PAI-1 
was also found to be significantly associated with a history of thrombosis [110]. The data on 
sICAM-1 in SLE are limited. Upregulated expression of sICAM was reported to be associated 
with increased disease activity in SLE [108]. The role of sICAM-1 in the atherogenesis in the 
general population is recognized. It was reported that sICAM-1 was expressed in human 
atherosclerotic plaques [131]. However, our study was the first to demonstrate the relationship 
between sICAM-1 and subclinical vascular disease in SLE. 
Other inflammatory markers evaluated in our study, such as CRP, fibrinogen, albumin, 
E-selectin and CD40L, were not found to be independently associated with the presence or 
severity of EBT-detected atherosclerosis. The existing data on these variables are either limited 
or contradictory. For instance, on the one hand, studies conducted on SLE patients showed that 
CRP was independently associated with intima-media thickness of the carotid artery [111], with 
congestive heart failure (CHF) [132], vascular events (cardio-, cerebrovascular and peripheral 
vascular) [133], and with a history of CVD [129]. On the other hand, it was also reported that in 
patients with SLE, elevated CRP is associated with increased risk of death but not with 
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atherosclerosis [134]. Also, no association was found between elevated CRP and coronary 
calcification [99] and presence of carotid plaque [98]. The lack of relationship of inflammatory 
markers with atherosclerosis observed in lupus, particularly cross-sectionally, can be partially 
explained by elevated baseline level of these parameters in SLE patients in comparison to non-
lupus subjects. This latter phenomenon was described by Svenungsson et al. [129], and 
confirmed by the descriptive analysis of our data showing abnormally high CRP levels. 
Prospective studies are needed to establish the true relationship between the inflammatory 
markers and development of atherosclerosis in SLE population.  
Since the development of vascular disease is recognized to be associated with 
menopausal loss of estrogen protective effect, we described characteristics of pre- and 
postmenopausal patients according to the presence or absence of calcification in the coronary 
artery and aorta. Some trends in risk factors were noticed in pre- and postmenopausal groups of 
women. Both groups of patients were almost equally subjected to traditional risk factors for 
coronary calcification; in premenopausal women, calcification was associated with fewer SLE-
related variables but with more inflammatory markers compared to postmenopausal group. In 
fact, in the premenopausal group, all inflammatory markers measured were significantly 
associated with coronary calcification, while in the postmenopausal group, only half of the 
markers was significantly associated with the outcome.  These findings may suggest that in 
premenopausal women, an otherwise low-risk demographic group, inflammatory mechanisms 
particularly contribute to atherogenesis. A larger sample size is required to study the independent 
relationship between calcification and inflammatory markers in multivariate analysis. 
We found that the development of atherosclerosis in the two vessel beds, coronary and 
carotid, is strongly correlated. This finding is consistent with systemic nature of atherosclerosis 
and its ability to affect several vascular beds. Previously conducted autopsy series have shown 
an association between carotid and coronary atherosclerosis [135,136]. Significant association 
between focal plaque, increased IMT, and prevalent and incident coronary events has also been 
reported in non-lupus population-based cohorts [137-140]. 
The findings are weakened by a few study limitations. Although SLE is more prevalent in 
black population, the cohort of this study mostly consisted of white women. This reduces 
generalizability of the study results. The true calcification frequency in the lupus population 
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could have been underestimated, and other risk factors associated with coronary and aortic 
calcification could have been not detected due to this problem.  
In addition, the cross-sectional study design makes it impossible to establish temporal 
relationships or causality. Further prospective studies may help not only to resolve this problem, 
but also to address the issue of fluctuating SLE activity, which can be associated with changes in 
many atherogenic-related factors.  
 
3.5 SUMMARY 
In conclusion, our findings confirm that the prevalence of atherosclerosis is significantly 
increased among patients with lupus. As in general population, atherogenesis starts earlier in the 
aorta than in the coronary artery. There is a significant correlation in the development of 
atherosclerosis in the carotid and coronary vessel beds. Traditional cardiovascular, lupus-related 
and inflammatory risk factors constitute predictors of coronary and aortic calcification in SLE 
cohort. In premenopausal SLE patients, development of atherosclerosis is significantly 
determined by chronic inflammation. This suggests additional potential targets to reduce the risk 
of cardiovascular disease in these patients.    
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APPENDIX  SENSITIVITY ANALYSIS OF THE THERAPEUTIC 
THRESHOLD 
 
The sensitivity of the therapeutic treatment with respect to the SLE incidence, probability of 
dying from SLE, probability of dying from SLE under early diagnosis, and probability of dying 
from causes other than SLE are presented in Figure A-3 to Figure A-6. 
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Figure A-3. Sensitivity of therapeutic threshold 
with respect to SLE incidence  
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Figure A-4. Sensitivity of therapeutic threshold 
with respect to the probability of dying from SLE 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0 0.0005 0.001
pSLEImprovDeath
Th
er
ap
eu
tic
 th
re
sh
ol
d
 
Figure A-5. Sensitivity of therapeutic threshold 
with respect to the probability of dying from SLE 
under early diagnosis 
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Figure A-6. Sensitivity of therapeutic threshold 
with respect to the probability of dying from causes 
other than SLE 
The therapeutic threshold probability also depends on the ratio between utilities of 
patients with SLE (uSLE), patients with early diagnosed SLE (uEarlySLE), and patients with 
no SLE who nevertheless undergone prophylactic SLE treatment and suffer from side effects 
(uTox). Average utility of patients with SLE is based on the literature [91] and is fixed at 
0.62. The utility of SLE with early diagnosis and utility of side effects are assumed to be 
higher. We run sensitivity analyses on these variables (Figure A-7 and Figure A-8).  
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The therapeutic threshold proves to be the most sensitive to the utility of side effects 
denoted as uTox (see Figure A-8).  
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Figure A-7. Sensitivity of therapeutic threshold with respect to the utility of early diagnosed SLE 
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Figure A-8. Sensitivity of Therapeutic threshold with respect to the utility of side effect
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